CUMULATIVE
SUPPLEMENT 11
NOV'99



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGMENT AND SERVICES

1999

Approved drug products with therapeutic equivalence

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

CONTENTS

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 11

NOVEMBER 1999

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

CUMULATIVE SUPPLEMENT 11
NOVEMBER 1999

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)	ASTRA ZENECA LP (ASTRA ZENECA)
PENEDERM INC (PENEDERM)	BERTEK PHARMACEUTICALS (BERTEK PHARMS)
SANOFI PHARMACEUTICALS INC (SANOFI)	SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $90.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/19bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1998	MAR 1999	JUN 1999	SEP 1999
DRUG PRODUCTS LISTED	9923	9975	10009	9939
SINGLE SOURCE	2504 (25.2%)	2520 (25.3%)	2523 (25.2%)	2557 (25.7%)
MULTISOURCE	7308 (73.6%)	7344 (73.6%)	7375 (73.7%)	7271 (73.2%)
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	6969 (69.9%)	7012 (70.1%)	6923 (69.7%)
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	375 (3.8%)	363 (3.6%)	348 (3.5%)
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	10	3	5	13
NUMBER OF APPLICANTS	563	570	568	572

[1] Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; BUTALBITAL; CAPSULE

CAPSULE; ORAL

	BUTALBITAL, ACETAMINOPHEN, CAFFEINE			
AB	GRAHAM DM	**325MG;50MG;40MG**	**N88758 001**	**MAR 27, 1985**
	@ MALLINCKRODT	325MG;50MG;40MG	N88758 001	MAR 27, 1985
	FEMCET			
AB	MALLINCKRODT	**325MG;50MG;40MG**	**N89102 001**	**JUN 19, 1985**
	@	325MG;50MG;40MG	N89102 001	JUN 19, 1985
	TRIAD			
AB	MALLINCKRODT	**325MG;50MG;40MG**	**N89023 001**	**JUN 19, 1985**
	@	325MG;50MG;40MG	N89023 001	JUN 19, 1985

TABLET; ORAL

	BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE			
AB	WEST WARD	**500MG;50MG;40MG**	**N40336 001**	**AUG 18, 1999**

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE			
+	MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ALLAY			
AA	NORTON HN	**500MG;5MG**	**N89907 001**	**JAN 13, 1989**
AA	ZENITH GOLDLINE	**500MG;5MG**	**N89907 001**	**JAN 13, 1989**
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MALLINCKRODT	**500MG;5MG**	**N88956 001**	**JUL 19, 1985**
	ZYDONE			
AA	MALLINCKRODT	**500MG;5MG**	**N88956 001**	**JUL 19, 1985**

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN			
AA	DURAMED	**500MG;5MG**	**N40289 001**	**MAR 16, 1999**

TABLET; ORAL

	OXYCODONE AND ACETAMINOPHEN			
AA	AMIDE PHARM	**325MG;5MG**	**N40203 001**	**MAR 15, 1999**
	PERCOCET			
	ENDO PARMS	325MG;2.5MG	N40330 001	JUN 25, 1999
AA	ENDO PHARMS	**325MG;5MG**	**N40330 002**	**JUN 25, 1999**
+		325MG;2.5MG	N40330 001	JUN 25, 1999
+		500MG;7.5MG	N40341 001	JUL 26, 1999
+		650MG;10MG	N40341 002	JUL 26, 1999

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPACET 100			
AB	TEVA	**650MG;100MG**	**N70107 001**	**JUN 12, 1985**
	@	650MG;100MG	N70107 001	JUN 12, 1985

ACITRETIN

CAPSULE; ORAL

	SORIATANE			
	HLR	10MG	N19821 001	OCT 28, 1996
+		25MG	N19821 002	OCT 28, 1996
	ROCHE	10MG	N19821 001	OCT 28, 1996
+		25MG	N19821 002	OCT 28, 1996

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	STASON	200MG	N75090 001	JAN 26, 1999

TABLET; ORAL
ACYCLOVIR

AB	CARLSBAD	400MG	N75382 001	APR 30, 1999
AB		800MG	N75382 002	APR 30, 1999

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR

AP	ABBOTT	EQ 50MG BASE/ML	N75114 001	JUL 26, 1999

ACYCLOVIR SODIUM

AP	+ AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001	MAY 13, 1998
	+	EQ 50MG BASE/ML	N74930 001	MAY 13, 1998
AP	MERIDIAN MEDCL TECHN	EQ 50MG BASE/ML	N75065 001	FEB 25, 1999

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

AB	MEDEVA	0.09MG/INH	N72273 001	AUG 14, 1996
AB	MEDEVA PHARMS MA	0.09MG/INH	N72273 001	AUG 14, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	HI TECH PHARMA	EQ 0.083% BASE	N75063 001	FEB 09, 1999
> ADD > AN	MORTON GROVE	EQ 0.083% BASE	N75394 001	NOV 22, 1999

> ADD >

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

> ADD > AN	STERIPAK	EQ 0.083% BASE	N75343 001	NOV 09, 1999

> ADD >

SYRUP; ORAL
ALBUTEROL SULFATE

AA	UDL	EQ 2MG BASE/5ML	N75262 001	MAR 30, 1999

VENTOLIN

AA	+ GLAXO WELLCOME	EQ 2MG BASE/5ML	N19621 001	JUN 10, 1987
	@	EQ 2MG BASE/5ML	N19621 001	JUN 10, 1987

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION
ALCOHOL 5% IN DEXTROSE 5% IN WATER

AP	BAXTER HLTHCARE	5ML/100ML;5GM/100ML	N83256 001	
	@	5ML/100ML;5GM/100ML	N83256 001	

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ALFENTA

AP	+ AKORN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986
	+	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986

ALFENTANIL

AP	ABBOTT	EQ 0.5MG BASE/ML	N75221 001	OCT 28, 1999

ALITRETINOIN

GEL; TOPICAL
PANRETIN

	+ LIGAND	EQ 0.1% BASE	N20886 001	FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM

AB		FARO PHARMS	100MG	N16084 001
AB	+		300MG	N16084 002
AB		GLAXO WELLCOME	100MG	N16084 001
AB	+		300MG	N16084 002

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM

+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996

ZYLOPRIM

+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12

+	BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL	N20924 001 APR 06, 1999

ALPRAZOLAM

CONCENTRATE; ORAL
ALPRAZOLAM

	ROXANE	1MG/ML	N74312 001 OCT 31, 1993
+		1MG/ML	N74312 001 OCT 31, 1993

SOLUTION; ORAL
ALPRAZOLAM

	ROXANE	0.5MG/5ML	N74314 001 OCT 31, 1993

ALPRAZOLAM

SOLUTION; ORAL
ALPRAZOLAM

+	ROXANE	0.5MG/5ML	N74314 001 OCT 31, 1993

TABLET; ORAL
ALPRAZOLAM

AB	ALPHAPHARM	2MG	N74046 004 MAY 07, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	GENSIA SICOR PHARMS	0.5MG/ML	N75196 001 APR 30, 1999

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT

@	FUJISAWA HLTHCARE	0.025%	N18116 001
+		0.1%	N18116 002
	LEDERLE	0.025%	N18116 001
+		0.1%	N18116 002

LOTION; TOPICAL
CYCLOCORT

+	FUJISAWA HLTHCARE	0.1%	N19729 001 JUN 13, 1988
+	LEDERLE	0.1%	N19729 001 JUN 13, 1988

OINTMENT; TOPICAL
CYCLOCORT

+	FUJISAWA HLTHCARE	0.1%	N18498 001
+	WYETH AYERST	0.1%	N18498 001

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL

	US BIOSCIENCE	375MG/VIAL	N20221 002 SEP 10, 1999

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE			
FRESENIUS KABI	5.2%		N18901 001 APR 06, 1984
PHARMACIA AND UPJOHN	5.2%		N18901 001 APR 06, 1984
NEOPHAM 6.4%			
@ FRESENIUS KABI	6.4%		N18792 001 JAN 17, 1984
@ PHARMACIA AND UPJOHN	6.4%		N18792 001 JAN 17, 1984
NOVAMINE 11.4%			
FRESENIUS KABI	11.4%		N17957 003 AUG 09, 1982
PHARMACIA AND UPJOHN	11.4%		N17957 003 AUG 09, 1982
NOVAMINE 15%			
FRESENIUS KABI	15%		N17957 004 NOV 28, 1986
PHARMACIA AND UPJOHN	15%		N17957 004 NOV 28, 1986
NOVAMINE 8.5%			
@ FRESENIUS KABI	8.5%		N17957 002 AUG 09, 1982
@ PHARMACIA AND UPJOHN	8.5%		N17957 002 AUG 09, 1982

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%			
@ FRESENIUS KABI	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML		N17957 001
@ PHARMACIA AND UPJOHN	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML		N17957 001

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE		
AP	SMITH AND NEPHEW	25MG/ML	N88749 001 MAY 30, 1985
@		25MG/ML	N88749 001 MAY 30, 1985

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

	AMIODARONE HCL		
AB	ALPHAPHARM	200MG	N75188 001 FEB 24, 1999
AB	NOVOPHARM	200MG	N74895 001 APR 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	AMITRIPTYLINE HCL		
AP	STERIS	10MG/ML	N85594 001
	@	10MG/ML	N85594 001
	ELAVIL		
AP	+ ZENECA	10MG/ML	N12704 001
	+	10MG/ML	N12704 001

TABLET; ORAL

	AMITRIPTYLINE HCL		
BP	COPLEY PHARM	10MG	N88421 001 APR 30, 1984
BP		25MG	N88422 001 APR 30, 1984
BP		50MG	N88423 001 APR 30, 1984
BP		75MG	N88424 001 APR 30, 1984
BP		100MG	N88425 001 APR 30, 1984
BP		150MG	N88426 001 APR 30, 1984
	@	10MG	N88421 001 APR 30, 1984
	@	25MG	N88422 001 APR 30, 1984
	@	50MG	N88423 001 APR 30, 1984
	@	75MG	N88424 001 APR 30, 1984
	@	100MG	N88425 001 APR 30, 1984
	@	150MG	N88426 001 APR 30, 1984
	ENDEP		
AB	ROCHE	10MG	N83639 001
AB		25MG	N83639 002

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	ENDEP		
AB	**ROCHE**	**50MG**	**N83639 003**
AB		**75MG**	**N83639 004**
AB		**100MG**	**N83639 005**
	@	10MG	N83639 001
	@	25MG	N83639 002
	@	50MG	N83639 003
	@	75MG	N83639 004
	@	100MG	N83639 005

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN		
AB	RANBAXY	**250MG**	**N65016 001** APR 08, 1999
AB		**500MG**	**N65016 002** APR 08, 1999

POWDER FOR RECONSTITUTION; ORAL

	AMOXIL		
	SMITHKLINE BEECHAM	200MG/5ML	N50760 001 APR 15, 1999
+		400MG/5ML	N50760 002 APR 15, 1999

TABLET; ORAL

	AMOXIL		
> DLT >	+ SMITHKLINE BEECHAM	500MG	N50754 002 JUL 10, 1998
> DLT >			
> ADD >		500MG	N50754 002 JUL 10, 1998
> ADD >			

TABLET, CHEWABLE; ORAL

	AMOXIL		
	SMITHKLINE BEECHAM	200MG	N50761 001 APR 15, 1999
+		400MG	N50761 002 APR 15, 1999

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

	AMPHOTEC		
+	ALZA	50MG/VIAL	N50729 001 NOV 22, 1996
+		100MG/VIAL	N50729 002 NOV 22, 1996
+	SEQUUS	50MG/VIAL	N50729 001 NOV 22, 1996
+		100MG/VIAL	N50729 002 NOV 22, 1996

AMPRENAVIR

CAPSULE; ORAL

	AGENERASE		
	GLAXO WELLCOME	50MG	N21007 001 APR 15, 1999
+		150MG	N21007 002 APR 15, 1999

SOLUTION; ORAL

	AGENERASE		
+	GLAXO WELLCOME	15MG/ML	N21039 001 APR 15, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

	KABIVITE PED F + W KIT		
+	FRESENIUS KABI	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A	N20176 001 DEC 29, 1993

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT
+ PHARMACIA AND UPJOHN N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A — N20176 001 DEC 29, 1993

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001	MAR 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	STEVENS J	385MG;30MG;25MG	N74988 001	APR 30, 1999
AB		770MG;60MG;50MG	N74988 002	APR 30, 1999

> ADD > ASPIRIN; DIPYRIDAMOLE

> ADD > CAPSULE, EXTENDED RELEASE; ORAL
> ADD > AGGRENOX
> ADD > + BOEHRINGER INGELHEIM 25MG;200MG — N20884 001 NOV 22, 1999
> ADD >

ASTEMIZOLE

TABLET; ORAL
HISMANAL
+ JANSSEN 10MG — N19402 001 DEC 29, 1988

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	APOTHECON	50MG	N73317 001	MAR 20, 1992
AB		100MG	N73318 001	MAR 20, 1992
@		50MG	N73317 001	MAR 20, 1992
@		100MG	N73318 001	MAR 20, 1992
	MYLAN	25MG	N73457 002	APR 26, 1999

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
TRACRIUM

> ADD > AP	+ ABBOTT	10MG/ML	N18831 002	JUN 20, 1985
> ADD >				
> DLT > AP	+ GLAXO WELLCOME	10MG/ML	N18831 002	JUN 20, 1985
> DLT >				

TRACRIUM PRESERVATIVE FREE

> ADD > AP	+ ABBOTT	10MG/ML	N18831 001	NOV 23, 1983
> ADD >				
> DLT > AP	+ GLAXO WELLCOME	10MG/ML	N18831 001	NOV 23, 1983
> DLT >				

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA	PHARMERAL	0.025MG;2.5MG	N85035 001	
AA	R AND S PHARMA	0.025MG;2.5MG	N85035 001	

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	ZENITH GOLDLINE	0.025MG;2.5MG	N86727 001	
@		0.025MG;2.5MG	N86727 001	

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE

AB	APPLIED ANAL	50MG	N75252 001	JUN 07, 1999

IMURAN

AB	+ FARO PHARMS	50MG	N16324 001	

AZATHIOPRINE

TABLET; ORAL
IMURAN
@ FARO PHARMS 25MG N16324 002
AB + GLAXO WELLCOME 50MG N16324 001
@ 25MG N16324 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
IMURAN
AP + FARO PHARMS EQ 100MG BASE/VIAL N17391 001
AP + GLAXO WELLCOME EQ 100MG BASE/VIAL N17391 001

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

POWDER FOR RECONSTITUTION, TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK
+ PFIZER EQ 1GM BASE,N/A;N/A, EQ 100MG BASE N50762 001 DEC 18, 1998
@ EQ 1GM BASE,N/A;N/A, EQ 100MG BASE N50762 001 DEC 18, 1998

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE
AT + ALTANA 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N60731 002
@ 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N60731 002
AT PHARMADERM 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62166 002
+ 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62166 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE
APOTHECON 5MG;40MG N18647 001 MAY 25, 1983

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE
+ APOTHECON 5MG;80MG N18647 002 MAY 25, 1983
BRISTOL MYERS SQUIBB 5MG;40MG N18647 001 MAY 25, 1983
+ 5MG;80MG N18647 002 MAY 25, 1983

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN
+ BAYER 60 UMOLAR N50114 001
+ HOLLISTER STIER LABS 60 UMOLAR N50114 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE
AB ALTANA EQ 0.05% BASE N75373 001 JUN 22, 1999

BETAMETHASONE VALERATE

AEROSOL; TOPICAL
LUXIQ
+ CONNETICS EQ 0.12% BASE N20934 001 FEB 28, 1999

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL
BETAXOLOL HCL
AB AMIDE PHARM 10MG N75541 001 OCT 22, 1999
AB 20MG N75541 002 OCT 22, 1999
KERLONE
AB LOREX 10MG N19507 001 OCT 27, 1989
AB + 20MG N19507 002 OCT 27, 1989

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

	KERLONE			
	LOREX	10MG	N19507 001	
			OCT 27, 1989	
+		20MG	N19507 002	
			OCT 27, 1989	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE			
AP	ASTRA PHARMS	**50MG/ML**	**N71153 001**	
			AUG 10, 1987	
	@ ASTRAZENECA	50MG/ML	N71153 001	
			AUG 10, 1987	

BUDESONIDE

SPRAY, METERED; NASAL

	RHINOCORT			
	ASTRAZENECA	0.032MG/INH	N20746 001	
			OCT 01, 1999	
+		0.064MG/INH	N20746 002	
			OCT 01, 1999	

BUPROPION HYDROCHLORIDE

TABLET; ORAL

> ADD >		**BUPROPION HCL**			
> ADD >	**AB**	TEVA	**75MG**	**N75310 001**	
> ADD >				NOV 29, 1999	
> ADD >	**AB**		**100MG**	**N75310 002**	
> ADD >				NOV 29, 1999	
		WELLBUTRIN			
> ADD >	**AB**	GLAXO WELLCOME	**75MG**	**N18644 002**	
> ADD >				DEC 30, 1985	
> ADD >	**AB**	+	**100MG**	**N18644 003**	
> ADD >				DEC 30, 1985	
> DLT >			75MG	N18644 002	
> DLT >				DEC 30, 1985	
> DLT >		+	100MG	N18644 003	
> DLT >				DEC 30, 1985	

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	WELLBUTRIN			
+	GLAXO WELLCOME	50MG	N20358 001	
			OCT 04, 1996	
+		100MG	N20358 002	
			OCT 04, 1996	
+		150MG	N20358 003	
			OCT 04, 1996	
	WELLBUTRIN SR			
+	GLAXO WELLCOME	50MG	N20358 001	
			OCT 04, 1996	
+		100MG	N20358 002	
			OCT 04, 1996	
+		150MG	N20358 003	
			OCT 04, 1996	

BUSULFAN

INJECTABLE; INJECTION

	BUSULFEX			
+	ORPHAN MEDCL	6MG/ML	N20954 001	
			FEB 04, 1999	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

	FEMSTAT			
+	SYNTEX	2%	N19215 001	
			NOV 25, 1985	
	@	2%	N19215 001	
			NOV 25, 1985	
	FEMSTAT ONE			
+	KV PHARM	2%	N19881 001	
			FEB 07, 1997	
+	SYNTEX	2%	N19881 001	
			FEB 07, 1997	

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

		BUTORPHANOL TARTRATE			
> ADD >	**AP**	MERIDIAN MEDCL TECHN	**1MG/ML**	**N75342 001**	
> ADD >				NOV 04, 1999	

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

> ADD > **AP** MERIDIAN MEDCL TECHN **2MG/ML** **N75342 002**
> ADD NOV 04, 1999

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
CAFCIT

\+ OPR DEVELOP LP EQ 10MG BASE/ML N20793 001
SEP 21, 1999

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA

AT AKORN **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N20079 001**
NOV 27, 1991

AT ALLERGAN **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N20079 001**
NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001

@ 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N18269 002
JAN 17, 1983

@ 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N18269 002
JAN 17, 1983

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE

\+ ONY 35MG/ML N20521 001
JUL 01, 1998

SUSPENSION; INTRATRACHEAL
INFASURF PRESERVATIVE FREE

\+ ONY 35MG/ML N20521 001
JUL 01, 1998

CAPECITABINE

TABLET; ORAL
XELODA

HLR 150MG N20896 001
APR 30, 1998

ROCHE 150MG N20896 001
APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB BAKER NORTON **12.5MG** **N74590 004**
AUG 30, 1996

AB **25MG** **N74590 002**
AUG 30, 1996

AB **50MG** **N74590 001**
AUG 30, 1996

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL			
AB	**BAKER NORTON**	**100MG**	**N74590 003**	**AUG 30, 1996**
AB	ZENITH GOLDLINE	**12.5MG**	**N74590 004**	AUG 30, 1996
AB		**25MG**	**N74590 002**	AUG 30, 1996
AB		**50MG**	**N74590 001**	AUG 30, 1996
AB		**100MG**	**N74590 003**	AUG 30, 1996

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

	GEOPEN			
+	ROERIG	EQ 1GM BASE/VIAL	N50306 001	
+		EQ 2GM BASE/VIAL	N50306 004	
+		EQ 5GM BASE/VIAL	N50306 002	
+		EQ 10GM BASE/VIAL	N50306 006	
+		EQ 30GM BASE/VIAL	N50306 007	
@		EQ 1GM BASE/VIAL	N50306 001	
@		EQ 2GM BASE/VIAL	N50306 004	
@		EQ 5GM BASE/VIAL	N50306 002	
@		EQ 10GM BASE/VIAL	N50306 006	
@		EQ 30GM BASE/VIAL	N50306 007	

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

	CARBIDOPA AND LEVODOPA			
AB	MYLAN	**50MG;200MG**	**N75091 001**	SEP 30, 1999
	SINEMET CR			
AB	+ DUPONT PHARMS	**50MG;200MG**	**N19856 001**	MAY 30, 1991
	+	50MG;200MG	N19856 001	MAY 30, 1991

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	OCUPRESS			
+	CIBA	1%	N19972 001	MAY 23, 1990
+	OTSUKA	1%	N19972 001	MAY 23, 1990

CEFACLOR

CAPSULE; ORAL

	CEFACLOR			
AB	**LEDERLE**	**EQ 250MG BASE**	**N64107 001**	APR 27, 1995
AB		**EQ 500MG BASE**	**N64107 002**	APR 27, 1995
@		EQ 250MG BASE	N64107 001	APR 27, 1995
@		EQ 500MG BASE	N64107 002	APR 27, 1995
AB	**TEVA**	**EQ 250MG BASE**	**N64081 001**	SEP 16, 1996
AB		**EQ 500MG BASE**	**N64081 002**	SEP 16, 1996
@		EQ 250MG BASE	N64081 001	SEP 16, 1996
@		EQ 500MG BASE	N64081 002	SEP 16, 1996

POWDER FOR RECONSTITUTION; ORAL

	CEFACLOR			
AB	**LEDERLE**	**EQ 125MG BASE/5ML**	**N64114 001**	APR 28, 1995
AB		**EQ 187MG BASE/5ML**	**N64115 001**	APR 28, 1995
AB		**EQ 250MG BASE/5ML**	**N64116 001**	APR 28, 1995
AB		**EQ 375MG BASE/5ML**	**N64110 001**	APR 28, 1995
@		EQ 125MG BASE/5ML	N64114 001	APR 28, 1995
@		EQ 187MG BASE/5ML	N64115 001	APR 28, 1995
@		EQ 250MG BASE/5ML	N64116 001	APR 28, 1995
@		EQ 375MG BASE/5ML	N64110 001	APR 28, 1995

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

		CEFADROXIL		
AB		BARR	EQ 500MG BASE	N65015 001 JUN 22, 1999

POWDER FOR RECONSTITUTION; ORAL

		CEFADROXIL		
AB		APOTHECON	EQ 125MG BASE/5ML	N62334 001
AB			EQ 250MG BASE/5ML	N62334 002
AB			EQ 500MG BASE/5ML	N62334 003
	@		EQ 125MG BASE/5ML	N62334 001
	@		EQ 250MG BASE/5ML	N62334 002
	@		EQ 500MG BASE/5ML	N62334 003
		DURICEF		
AB	+	BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002
AB	+		EQ 250MG BASE/5ML	N50527 003
AB	+		EQ 500MG BASE/5ML	N50527 001
	+		EQ 125MG BASE/5ML	N50527 002
	+		EQ 250MG BASE/5ML	N50527 003
	+		EQ 500MG BASE/5ML	N50527 001

TABLET; ORAL

		CEFADROXIL		
AB		RANBAXY	EQ 1GM BASE	N65018 001 APR 23, 1999
		ULTRACEF		
AB		APOTHECON	EQ 1GM BASE	N62390 001 JUN 10, 1982
	@		EQ 1GM BASE	N62390 001 JUN 10, 1982

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

		CEPTAZ		
AP	+	GLAXO WELLCOME	1GM/VIAL	N50646 002 SEP 27, 1990
AP	+		2GM/VIAL	N50646 003 SEP 27, 1990
AP	+		10GM/VIAL	N50646 004 SEP 27, 1990
	+		1GM/VIAL	N50646 002 SEP 27, 1990
	+		2GM/VIAL	N50646 003 SEP 27, 1990

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

		CEPTAZ		
	+	GLAXO WELLCOME	10GM/VIAL	N50646 004 SEP 27, 1990
		PENTACEF		
AP		SMITHKLINE BEECHAM	1GM/VIAL	N63322 001 NOV 07, 1995
AP			1GM/VIAL	N64006 001 MAR 31, 1992
AP			2GM/VIAL	N63322 002 NOV 07, 1995
AP			2GM/VIAL	N64006 002 MAR 31, 1992
AP			10GM/VIAL	N64008 002 MAR 31, 1992
			6GM/VIAL	N64008 001 MAR 31, 1992
	@		1GM/VIAL	N63322 001 NOV 07, 1995
	@		1GM/VIAL	N64006 001 MAR 31, 1992
	@		2GM/VIAL	N63322 002 NOV 07, 1995
	@		2GM/VIAL	N64006 002 MAR 31, 1992
	@		6GM/VIAL	N64008 001 MAR 31, 1992
	@		10GM/VIAL	N64008 002 MAR 31, 1992

CEFUROXIME SODIUM

INJECTABLE; INJECTION

		CEFUROXIME		
AB		ASTRA PHARMS	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP			EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP			EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998
AB		TEVA	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP			EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP			EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	RANBAXY	EQ 250MG BASE	N65007 001 SEP 16, 1999
AB		EQ 500MG BASE	N65007 002 SEP 16, 1999

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM

AP	ABBOTT	EQ 1GM BASE/VIAL	N62547 001 SEP 11, 1985
AP		EQ 2GM BASE/VIAL	N62547 002 SEP 11, 1985
	@	EQ 1GM BASE/VIAL	N62547 001 SEP 11, 1985
	@	EQ 2GM BASE/VIAL	N62547 002 SEP 11, 1985

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

	+ BAYER	0.3MG	N20740 004 JUN 26, 1997
		0.3MG	N20740 004 JUN 26, 1997
	+	0.4MG	N20740 005 MAY 24, 1999

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL

> ADD >	AT	ALCON	0.5%	N62628 001 SEP 25, 1985
> ADD >				
> DLT >	AT	STERIS	0.5%	N62628 001 SEP 25, 1985
> DLT >				

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
A-POXIDE

	@ ABBOTT	5MG	N85517 001
	@	5MG	N85517 001
	CHLORDIAZEPOXIDE HCL		
AB	MAST MM	10MG	N86217 001
	@	10MG	N86217 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA	MD PHARM	EQ 150MG BASE	N87228 001
	@	EQ 150MG BASE	N87228 001
AA	WEST WARD	EQ 300MG BASE	N83082 002 SEP 17, 1999

CHLOROTRIANISENE

CAPSULE; ORAL
CHLOROTRIANISENE

AA	BANNER PHARMACAPS	12MG	N84652 001
	@	12MG	N84652 001
	TACE		
AA	+ HOECHST MARION RSSL	12MG	N08102 004
	+	12MG	N08102 004

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
CHLORPROMAZINE HCL

AA	PHARM ASSOC	100MG/ML	N40224 001 JAN 26, 1999

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

AB	ABBOTT	25MG	N87364 001
	@	25MG	N87364 001
AB	DANBURY PHARMA	25MG	N87296 001
AB		25MG	N87706 001
AB		50MG	N87521 001

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE				
AB	DANBURY PHARMA	50MG	N87689 001		
@		25MG	N87296 001		
@		25MG	N87706 001		
@		50MG	N87521 001		
@		50MG	N87689 001		
AB	EON	50MG	N87118 001		
@		50MG	N87118 001		
AB	KV PHARM	25MG	N87311 001		
AB		50MG	N87312 001		
@		25MG	N87311 001		
@		50MG	N87312 001	> ADD >	
AB	LEDERLE	25MG	N87451 001	> ADD >	
AB		50MG	N87450 001	> DLT >	
@		25MG	N87451 001	> DLT >	
@		50MG	N87450 001		
				> ADD >	
				> ADD >	
				> ADD >	
				> ADD >	
				> DLT >	
				> DLT >	
				> DLT >	
				> DLT >	

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
AB	ZENITH GOLDLINE	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	EQ 4GM RESIN/SCOOPFUL	N74555 002	SEP 30, 1998

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CATARASE		
+	CIBA	300 UNITS/VIAL	N16938 001
@		300 UNITS/VIAL	N16938 001
	ZOLYSE		
	ALCON	750 UNITS/VIAL	N11903 001
+		750 UNITS/VIAL	N11903 001

CILOSTAZOL

TABLET; ORAL

	PLETAL		
	OTSUKA	50MG	N20863 001 JAN 15, 1999
+		100MG	N20863 002 JAN 15, 1999

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

	NIMBEX		
+	ABBOTT	EQ 2MG BASE/ML	N20551 001 DEC 15, 1995
+	GLAXO WELLCOME	EQ 2MG BASE/ML	N20551 001 DEC 15, 1995
	NIMBEX PRESERVATIVE FREE		
+	ABBOTT	EQ 2MG BASE/ML	N20551 003 DEC 15, 1995
+		EQ 10MG BASE/ML	N20551 002 DEC 15, 1995
+	GLAXO WELLCOME	EQ 2MG BASE/ML	N20551 003 DEC 15, 1995
+		EQ 10MG BASE/ML	N20551 002 DEC 15, 1995

CISPLATIN

INJECTABLE; INJECTION

	CISPLATIN		
AP	AM PHARM PARTNERS	1MG/ML	N74735 001 JUL 16, 1999
	PLATINOL-AQ		
AP +	BRISTOL MYERS	1MG/ML	N18057 004 NOV 08, 1988
+		1MG/ML	N18057 004 NOV 08, 1988

CLARITHROMYCIN

GRANULE, FOR RECONSTITUTION; ORAL

	BIAXIN		
	ABBOTT	187MG/5ML	N50698 003 SEP 30, 1998

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN HCL

AB	+ PHARMACIA AND UPJOHN	EQ 75MG BASE	N50162 001	> ADD >	
AB		EQ 75MG BASE	N50162 001	> ADD	
AB	+	EQ 150MG BASE	N50162 002	> DLT >	
AB		EQ 150MG BASE	N50162 002	> DLT >	
		EQ 300MG BASE	N50162 003		
			APR 14, 1988		
	+	EQ 300MG BASE	N50162 003		
			APR 14, 1988		

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	SOLOPAK	EQ 150MG BASE/ML	N62819 001
			MAR 15, 1988
AP		EQ 150MG BASE/ML	N62852 001
			MAR 17, 1988
	@	EQ 150MG BASE/ML	N62819 001
			MAR 15, 1988
	@	EQ 150MG BASE/ML	N62852 001
			MAR 17, 1988
AP	STERIS	EQ 150MG BASE/ML	N62900 001
			JUN 08, 1988
AP		EQ 150MG BASE/ML	N63079 001
			MAR 05, 1990
	@	EQ 150MG BASE/ML	N62900 001
			JUN 08, 1988
	@	EQ 150MG BASE/ML	N63079 001
			MAR 05, 1990

SUPPOSITORY; VAGINAL
CLEOCIN

+	PHARMACIA AND UPJOHN	100MG	N50767 001
			AUG 13, 1999

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB	ALPHARMA US PHARM	0.05%	N74139 001
			AUG 03, 1994
AB	NMC	0.05%	N74139 001
			AUG 03, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ALTANA	0.05%	N75430 001
			MAY 26, 1999
	@	0.05%	N75430 001
			MAY 26, 1999

GEL; TOPICAL
CLOBETASOL PROPIONATE

AB	TARO	0.05%	N75279 001
			MAY 28, 1999

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT	ALTANA	0.05%	N75391 001
			FEB 08, 1999

CLOMIPHENE CITRATE

TABLET; ORAL
CLOMIPHENE CITRATE

AB	PAR PHARM	50MG	N75528 001
			AUG 30, 1999

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXAPEN

AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001
AB		EQ 500MG BASE	N62233 002
	@	EQ 250MG BASE	N62233 001
	@	EQ 500MG BASE	N62233 002

POWDER FOR RECONSTITUTION; ORAL
CLOXACILLIN SODIUM

AA	TEVA	EQ 125MG BASE/5ML	N62268 001
	+	EQ 125MG BASE/5ML	N62268 001
	TEGOPEN		
AA	* APOTHECON	EQ 125MG BASE/5ML	N61453 001
	@	EQ 125MG BASE/5ML	N61453 001

CLOZAPINE

TABLET; ORAL

	CLOZAPINE			
AB	CREIGHTON	**25MG**	**N74546 001**	
			AUG 30, 1996	
AB		**100MG**	**N74546 002**	
			AUG 30, 1996	
AB	GENEVA PHARMS	**25MG**	**N74546 001**	
			AUG 30, 1996	
AB		**100MG**	**N74546 002**	
			AUG 30, 1996	
AB	MYLAN	**25MG**	**N75417 001**	
			MAY 27, 1999	
AB		**100MG**	**N75417 002**	
			MAY 27, 1999	

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

	COLISTIMETHATE			
AP	PHARMA TEK	**EQ 150MG BASE/VIAL**	**N64216 001**	
			FEB 26, 1999	
	COLY-MYCIN M			
AP	+ PARKEDALE	**EQ 150MG BASE/VIAL**	**N50108 002**	
	+	EQ 150MG BASE/VIAL	N50108 002	

CORTICOTROPIN

INJECTABLE; INJECTION

	CORTICOTROPIN			
AP	+ STERIS	**40 UNITS/VIAL**	**N88772 001**	
			NOV 21, 1984	
	@	40 UNITS/VIAL	N88772 001	
			NOV 21, 1984	

CROMOLYN SODIUM

CAPSULE; ORAL

	GASTROCROM			
	+ MEDEVA	100MG	N19188 001	
			DEC 22, 1989	
	@	100MG	N19188 001	
			DEC 22, 1989	

CROMOLYN SODIUM

SOLUTION; INHALATION

	CROMOLYN SODIUM			
AN	ALPHARMA	**10MG/ML**	**N75067 001**	
			JUL 19, 1999	
AN	MORTON GROVE	**10MG/ML**	**N75346 001**	
			OCT 25, 1999	
AN	ROXANE	**10MG/ML**	**N75175 001**	
			SEP 30, 1999	

SOLUTION/DROPS; OPHTHALMIC

	CROMOLYN SODIUM			
AT	ALCON	**4%**	**N75282 001**	
			JUN 16, 1999	
	CROMOPTIC			
AT	KING PHARMS	**4%**	**N75088 001**	
			APR 27, 1999	

CROTAMITON

LOTION; TOPICAL

	CROTAN			
AT	GALDERMA	**10%**	**N87204 001**	
AT	SUMMERS	**10%**	**N87204 001**	

CYANOCOBALAMIN

INJECTABLE; INJECTION

	RUVITE			
AP	SAVAGE LABS	**1MG/ML**	**N80570 002**	
	@	1MG/ML	N80570 002	

CYCLOPHOSPHAMIDE

TABLET; ORAL

	CYCLOPHOSPHAMIDE			
AB	ROXANE	**25MG**	**N40032 001**	
			AUG 17, 1999	
AB		**50MG**	**N40032 002**	
			AUG 17, 1999	
	CYTOXAN			
AB	BRISTOL MYERS SQUIBB	**25MG**	**N12141 002**	
AB	+	**50MG**	**N12141 001**	
		25MG	N12141 002	
	+	50MG	N12141 001	

CYCLOSPORINE

INJECTABLE; INJECTION

		CYCLOSPORINE		
AP		BEDFORD	**50MG/ML**	**N65004 001** OCT 29, 1999
		SANDIMMUNE		
AP	+	NOVARTIS	**50MG/ML**	**N50573 001** NOV 14, 1983
	+		50MG/ML	N50573 001 NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

		CYPROHEPTADINE HCL		
AA		MD PHARM	**4MG**	**N87566 001** NOV 10, 1982
	@		4MG	N87566 001 NOV 10, 1982

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

		CYSTEINE HCL		
	@	FRESENIUS KABI	7.25%	N19523 001 OCT 22, 1986
	@	PHARMACIA AND UPJOHN	7.25%	N19523 001 OCT 22, 1986

CYTARABINE

INJECTABLE; INJECTION

		CYTARABINE		
>ADD> **AP**		FAULDING	**2GM/VIAL**	**N75383 001** NOV 22, 1999

INJECTABLE, LIPOSOMAL; INJECTION

		DEPOCYT		
	+	DEPOTECH	10MG/ML	N21041 001 APR 01, 1999
	+	SKYEPHARMA	10MG/ML	N21041 001 APR 01, 1999

DACARBAZINE

INJECTABLE; INJECTION

		DACARBAZINE		
AP		AM PHARM PARTNERS	**100MG/VIAL**	**N75371 001** AUG 27, 1999
AP			**200MG/VIAL**	**N75371 002** AUG 27, 1999
		DTIC-DOME		
AP	+	BAYER	**100MG/VIAL**	**N17575 001**
	+		100MG/VIAL	N17575 001

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INJECTION

	SYNERCID		
	RHONE POULENC RORER	350MG/VIAL; EQ 150MG BASE/VIAL	N50747 001 SEP 21, 1999
		350MG/VIAL; EQ 150MG BASE/VIAL	N50748 001 SEP 21, 1999

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		CERUBIDINE		
AP	+	BEDFORD	**EQ 20MG BASE/VIAL**	**N64103 001** FEB 03, 1995
	+		EQ 20MG BASE/VIAL	N64103 001 FEB 03, 1995
		DAUNORUBICIN HCL		
	+	BEDFORD	EQ 5MG BASE/ML	N50731 001 JAN 30, 1998
AP		BIGMAR	**EQ 20MG BASE/VIAL**	**N65000 001** MAY 25, 1999
AP		GENSIA SICOR PHARMS	**EQ 20MG BASE/VIAL**	**N64212 001** JUN 23, 1998
		DAUNORUBICIN HCL PRESERVATIVE FREE		
AP	+	BEDFORD	**EQ 20MG BASE/VIAL**	**N50731 001** JAN 30, 1998
AP		GENSIA SICOR PHARMS	**EQ 20MG BASE/VIAL**	**N64212 001** JUN 23, 1998

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

		DDAVP		
AB	+	RHONE POULENC RORER	0.01MG/SPRAY	N17922 002 FEB 06, 1989
AB	+		0.01MG/SPRAY	N17922 003 AUG 07, 1996
	@		0.01MG/SPRAY	N17922 002 FEB 06, 1989
		DDAVP (NEEDS NO REFRIGERATION)		
AB	+	RHONE POULENC RORER	0.01MG/SPRAY	N17922 003 AUG 07, 1996
		DESMOPRESSIN ACETATE		
AB		BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001 JAN 25, 1999

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

		DESOGESTREL AND ETHINYL ESTRADIOL		
AB		DURAMED	0.15MG;0.03MG	N75256 001 AUG 12, 1999
		ORTHO-CEPT		
AB	+	JOHNSON RW	0.15MG;0.03MG	N20301 001 DEC 14, 1992
	+		0.15MG;0.03MG	N20301 001 DEC 14, 1992

TABLET; ORAL-28

		DESOGESTREL AND ETHINYL ESTRADIOL		
AB		DURAMED	0.15MG;0.03MG	N75256 002 AUG 12, 1999

DESONIDE

CREAM; TOPICAL

		TRIDESILON		
AB	+	BAYER	0.05%	N17010 001
AB	+	CLAY PARK	0.05%	N17010 001

OINTMENT; TOPICAL

		TRIDESILON		
AB	+	BAYER	0.05%	N17426 001
AB	+	CLAY PARK	0.05%	N17426 001

DEXAMETHASONE

SUSPENSION/DROPS; OPHTHALMIC

		DEXAMETHASONE		
AT		STERIS	0.1%	N89170 001 MAY 09, 1989
	@		0.1%	N89170 001 MAY 09, 1989
		MAXIDEX		
AT	+	ALCON	0.1%	N13422 001
	+		0.1%	N13422 001

TABLET; ORAL

		DEXONE 0.5		
BP		SOLVAY	0.5MG	N84991 001
	@		0.5MG	N84991 001
		DEXONE 0.75		
BP		SOLVAY	0.75MG	N84993 001
	@		0.75MG	N84993 001
		DEXONE 4		
BP		SOLVAY	4MG	N84992 001
	@		4MG	N84992 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		MAXITROL		
AT	+	ALCON	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50065 002
AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50065 002

SUSPENSION/DROPS; OPHTHALMIC

		MAXITROL		
AT	+	ALCON	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50023 002
AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50023 002

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION; OPHTHALMIC

		TOBRADEX		
	+	ALCON	0.1%;0.3%	N50592 001 AUG 18, 1988

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

	TOBRADEX			
AB	+ ALCON	0.1%;0.3%		N50592 001
				AUG 18, 1988
	TOBRAMYCIN AND DEXAMETHASONE			
AB	BAUSCH AND LOMB	0.1%;0.3%		N64134 001
				OCT 27, 1999

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	DECADRON			
AP	+ MERCK	EQ 24MG PHOSPHATE/ML		N12071 004
	+	EQ 24MG PHOSPHATE/ML		N12071 004
	DEXAMETHASONE SODIUM PHOSPHATE			
AP	STERIS	EQ 4MG PHOSPHATE/ML		N83702 001
AP		EQ 24MG PHOSPHATE/ML		N85606 001
	@	EQ 4MG PHOSPHATE/ML		N83702 001
	@	EQ 24MG PHOSPHATE/ML		N85606 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	DEXTROAMPHETAMINE SULFATE			
AA	ENDO PHARMS	5MG		N40299 001
				MAY 13, 1999

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 25%			
	ABBOTT	250MG/ML		N19445 002
				NOV 23, 1998

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	B BRAUN	2.5GM/100ML;450MG/100ML		N18030 001
	@	2.5GM/100ML;450MG/100ML		N18030 001
	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
	B BRAUN	5GM/100ML;110MG/100ML		N18030 005
	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
	@ B BRAUN	5GM/100ML;110MG/100ML		N18030 005
	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;200MG/100ML		N18030 004
	@	5GM/100ML;200MG/100ML		N18030 004
	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;330MG/100ML		N18030 003
	@	5GM/100ML;330MG/100ML		N18030 003
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;450MG/100ML		N18030 002
	@	5GM/100ML;450MG/100ML		N18030 002

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	MD-76			
AP	MALLINCKRODT	66%;10%		N87073 001
	@	66%;10%		N87073 001

DIAZEPAM

GEL; RECTAL

	DIASTAT			
	+ ATHENA	2.5MG/0.5ML		N20648 001
				JUL 29, 1997
		5MG/ML		N20648 002
				JUL 29, 1997
		10MG/2ML		N20648 003
				JUL 29, 1997
		15MG/3ML		N20648 004
				JUL 29, 1997
	+	20MG/4ML		N20648 005
				JUL 29, 1997
	+ ELAN PHARMS	2.5MG/0.5ML		N20648 001
				JUL 29, 1997
		5MG/ML		N20648 002
				JUL 29, 1997
		10MG/2ML		N20648 003
				JUL 29, 1997
		15MG/3ML		N20648 004
				JUL 29, 1997
	+	20MG/4ML		N20648 005
				JUL 29, 1997

DIAZEPAM

INJECTABLE; INJECTION

	DIAZEPAM			
AP	**STERIS**	**5MG/ML**	**N70911 001**	**AUG 28, 1986**
AP		**5MG/ML**	**N70930 001**	**DEC 01, 1986**
	@	5MG/ML	N70911 001	AUG 28, 1986
	@	5MG/ML	N70930 001	DEC 01, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL

	DICLOFENAC POTASSIUM			
AB	MYLAN	**50MG**	**N75463 001**	**JUL 26, 1999**

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	DICLOFENAC SODIUM			
AB	**ALCON**	**0.1%**	**N20809 001**	**MAY 04, 1998**
AB	FALCON PHARMS	**0.1%** †	**N20809 001**	**MAY 04, 1998**

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	MARTEC	**50MG**	**N74986 001**	**FEB 26, 1999**
AB		**75MG**	**N74986 002**	**FEB 26, 1999**
AB	NOVOPHARM	**50MG**	**N74723 001**	**MAR 30, 1999**
AB	SIDMAK LABS NJ	**50MG**	**N74432 002**	**JUL 29, 1999**
AB		**75MG**	**N74432 003**	**JUL 29, 1999**

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL			
AB	MYLAN	**10MG**	**N40319 001**	**SEP 07, 1999**

TABLET; ORAL

	DICYCLOMINE HCL			
AB	LANNETT	**20MG**	**N40230 001**	**FEB 26, 1999**
AB	MYLAN	**20MG**	**N40317 001**	**SEP 07, 1999**

DIDANOSINE

TABLET, CHEWABLE; ORAL

	VIDEX			
	BRISTOL MYERS SQUIBB	**25MG**	**N20154 002**	**OCT 09, 1991**
	+	**150MG**	**N20154 005**	**OCT 09, 1991**
	+	25MG	N20154 002	OCT 09, 1991
		150MG	N20154 005	OCT 09, 1991
		200MG	N20154 006	OCT 28, 1999

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE			
AB	TARO	**0.05%**	**N75331 001**	**MAY 14, 1999**

OINTMENT; TOPICAL

	DIFLORASONE DIACETATE			
AB	ALTANA	**0.05%**	**N75374 001**	**APR 27, 1999**
AB	TARO	**0.05%**	**N75331 001**	**MAY 14, 1999**
	PSORCON			
AB	+ PHARMACIA AND UPJOHN	**0.05%**	**N19260 001**	**AUG 28, 1985**
	+	**0.05%**	**N19260 001**	**AUG 28, 1985**

† SEE SECTION 1.3 OF INTRODUCTION

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB	PUREPAC PHARM	**250MG**	**N74285 001**	**MAY 07, 1996**
AB		**500MG**	**N74285 002**	**MAY 07, 1996**
	@	250MG	N74285 001	MAY 07, 1996
	@	500MG	N74285 002	MAY 07, 1996

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3 +	CARDERM	**120MG**	**N20062 001**	**AUG 10, 1992**
AB3 +		**180MG**	**N20062 002**	**DEC 27, 1991**
AB3 +		**240MG**	**N20062 003**	**DEC 27, 1991**
AB3 +		**300MG**	**N20062 004**	**DEC 27, 1991**
BC +		120MG	N20062 001	AUG 10, 1992
BC +		180MG	N20062 002	DEC 27, 1991
BC +		240MG	N20062 003	DEC 27, 1991
BC +		300MG	N20062 004	DEC 27, 1991

CARTIA XT

AB3	ANDRX PHARMS	**120MG**	**N74752 002**	**JUL 09, 1998**
AB3		**180MG**	**N74752 001**	**JUL 09, 1998**
AB3		**240MG**	**N74752 003**	**JUL 09, 1998**
AB3		**300MG**	**N74752 004**	**JUL 09, 1998**
	@	120MG	N74752 002	JUL 09, 1998
	@	180MG	N74752 001	JUL 09, 1998
	@	240MG	N74752 003	JUL 09, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARTIA XT

	@ ANDRX PHARMS	300MG	N74752 004	JUL 09, 1998

DILTIAZEM HCL

AB1	BIOVAIL	**60MG**	**N74845 001**	**SEP 15, 1999**
AB1		**90MG**	**N74845 002**	**SEP 15, 1999**
AB1		**120MG**	**N74845 003**	**SEP 15, 1999**

INJECTABLE; INJECTION

DILTIAZEM HCL

AP	APOTEX	**5MG/ML**	**N75375 001**	**SEP 30, 1999**
AP	MERIDIAN MEDCL TECHN	**5MG/ML**	**N75106 001**	**APR 29, 1999**

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

AA	PUREPAC PHARM	**25MG**	**N85156 001**	
AA		**50MG**	**N85150 001**	
	@	25MG	N85156 001	
	@	50MG	N85150 001	

ELIXIR; ORAL

HYDRAMINE

AA	ALPHARMA	**12.5MG/5ML**	**N80763 002**	
	@	12.5MG/5ML	N80763 002	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HCL

AT	ALCON	**0.1%**	**N73636 001**	**JUN 30, 1994**
AT	FALCON PHARMS	**0.1%**	**N73636 001**	**JUN 30, 1994**

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	PUREPAC PHARM	25MG	N89425 001	> ADD >	
			JUL 12, 1990	> ADD >	
AB		50MG	N89426 001	> DLT >	
			JUL 12, 1990	> DLT >	
	@	25MG	N89425 001		
			JUL 12, 1990		
	@	50MG	N89426 001		
			JUL 12, 1990		

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

+	LILLY	250MG	N50678 001
			JUN 19, 1995
+	LILLY RES LABS	250MG	N50678 001
			JUN 19, 1995

DOFETILIDE

CAPSULE; ORAL
TIKOSYN

	PFIZER	0.125MG	N20931 001
			OCT 01, 1999
		0.25MG	N20931 002
			OCT 01, 1999
+		0.5MG	N20931 003
			OCT 01, 1999

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	SMITH AND NEPHEW	40MG/ML	N70046 001
			AUG 29, 1985
AP		80MG/ML	N70047 001
			AUG 29, 1985
	@	40MG/ML	N70046 001
			AUG 29, 1985
	@	80MG/ML	N70047 001
			AUG 29, 1985

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION
NUROMAX

+	ABBOTT	EQ 1MG BASE/ML	N19946 001
			MAR 07, 1991
+	GLAXO WELLCOME	EQ 1MG BASE/ML	N19946 001
			MAR 07, 1991

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL

+	BONE CARE	2.5 UGM	N20862 001
			JUN 09, 1999

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL

+	ALZA	2MG/ML	N50718 001
			NOV 17, 1995
+	SEQUUS	2MG/ML	N50718 001
			NOV 17, 1995

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

@	PUREPAC PHARM	EQ 50MG BASE	N62479 001
			DEC 23, 1983
@		EQ 100MG BASE	N62479 002
			DEC 23, 1983
@	RANBAXY	EQ 50MG BASE	N62479 001
			DEC 23, 1983
@		EQ 100MG BASE	N62479 002
			DEC 23, 1983

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BENDECTIN

@	HOECHST MARION RSSL	10MG;10MG	N10598 002

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	SOLOPAK	2.5MG/ML	N71754 001 SEP 06, 1988
AP		2.5MG/ML	N71755 001 SEP 06, 1988
@		2.5MG/ML	N71754 001 SEP 06, 1988
@		2.5MG/ML	N71755 001 SEP 06, 1988
AP	STERIS	2.5MG/ML	N73520 001 NOV 27, 1991
AP		2.5MG/ML	N73521 001 NOV 27, 1991
AP		2.5MG/ML	N73523 001 NOV 27, 1991
@		2.5MG/ML	N73520 001 NOV 27, 1991
@		2.5MG/ML	N73521 001 NOV 27, 1991
@		2.5MG/ML	N73523 001 NOV 27, 1991

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL

+	ASTRAZENECA	5MG;2.5MG	N20668 002 OCT 28, 1998

ENTACAPONE

TABLET; ORAL
COMTAN

+	ORION	200MG	N20796 001 OCT 19, 1999

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE

+	FOREST LABS	5MG/ML	N07942 001

SUS-PHRINE SULFITE-FREE

	FOREST LABS	1.5MG/AMP	N07942 003 FEB 05, 1999

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE SULFITE-FREE

+	FOREST LABS	5MG/ML	N07942 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ELLENCE

+	PHARMACIA AND UPJOHN	2MG/ML	N50778 001 SEP 15, 1999

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN

	SMITHKLINE BEECHAM	EQ 300MG BASE	N20738 004 DEC 22, 1997
		EQ 400MG BASE	N20738 005 DEC 22, 1997
+		EQ 600MG BASE	N20738 006 MAY 27, 1999
	UNIMED PHARMS	EQ 300MG BASE	N20738 004 DEC 22, 1997
		EQ 400MG BASE	N20738 005 DEC 22, 1997
+		EQ 600MG BASE	N20738 006 MAY 27, 1999

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION
MEDIHALER ERGOTAMINE

+	3M	0.36MG/INH	N12102 001
@		0.36MG/INH	N12102 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

@	PARKE DAVIS	250MG	N62338 001
@	WARNER CHILCOTT	250MG	N62338 001

ERYTHROMYCIN

SOLUTION; TOPICAL

		C-SOLVE-2			
AT		BIOGLAN PHAR	2%	N62468 001	JUL 03, 1985
AT		ZENITH GOLDLINE	2%	N62468 001	JUL 03, 1985

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

		ALORA				
> DLT >	BX	PROCTER AND GAMBLE	0.05MG/24HR	N20655 001	DEC 20, 1996	
> DLT >	BX		0.075MG/24HR	N20655 002	DEC 20, 1996	
> DLT >	BX		0.1MG/24HR	N20655 003	DEC 20, 1996	
> ADD >	BX	WATSON LABS	0.05MG/24HR	N20655 001	DEC 20, 1996	
> ADD >	BX		0.075MG/24HR	N20655 002	DEC 20, 1996	
> ADD >	BX		0.1MG/24HR	N20655 003	DEC 20, 1996	
		CLIMARA				
	BX +	BERLEX LABS	0.025MG/24HR	N20375 004	MAR 05, 1999	
		ESCLIM				
	BX	FOURNIER	0.025MG/24HR	N20847 001	AUG 04, 1998	
	BX		0.0375MG/24HR	N20847 002	AUG 04, 1998	
	BX		0.05MG/24HR	N20847 003	AUG 04, 1998	
	BX		0.075MG/24HR	N20847 004	AUG 04, 1998	
	BX		0.1MG/24HR	N20847 005	AUG 04, 1998	
	BX	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847 001	AUG 04, 1998	
	BX		0.0375MG/24HR	N20847 002	AUG 04, 1998	
	BX		0.05MG/24HR	N20847 003	AUG 04, 1998	
	BX		0.075MG/24HR	N20847 004	AUG 04, 1998	
	BX		0.1MG/24HR	N20847 005	AUG 04, 1998	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

		ESCLIM				
	BX	WOMEN FIRST HLTHCARE	0.1MG/24HR	N20847 005	AUG 04, 1998	
		ESTRADIOL				
> ADD >	BX	CYGNUS CA	0.05MG/24HR	N21048 001	SEP 20, 1999	
> ADD >	BX		0.075MG/24HR	N21048 002	SEP 20, 1999	
> ADD >	BX		0.1MG/24HR	N21048 003	SEP 20, 1999	
	AB	MENOREST	**0.0375MG/24HR**	**N20538 001**	JUL 31, 1996	
	AB		**0.05MG/24HR**	**N20538 003**	JUL 31, 1996	
	AB		**0.075MG/24HR**	**N20538 002**	JUL 31, 1996	
	AB		**0.1MG/24HR**	**N20538 004**	JUL 31, 1996	
> DLT >	BX	WYETH AYERST	0.05MG/24HR	N21048 001	SEP 20, 1999	
> DLT >	BX		0.075MG/24HR	N21048 002	SEP 20, 1999	
> DLT >	BX		0.1MG/24HR	N21048 003	SEP 20, 1999	
		VIVELLE-DOT				
	AB	NOVARTIS	**0.0375MG/24HR**	**N20538 001**	JUL 31, 1996	
	AB		**0.05MG/24HR**	**N20538 003**	JUL 31, 1996	
	AB		**0.075MG/24HR**	**N20538 002**	JUL 31, 1996	
	AB		**0.1MG/24HR**	**N20538 004**	JUL 31, 1996	

TABLET; ORAL

	ESTRADIOL				
AB	MYLAN	**0.5MG**	**N40326 001**	APR 21, 1999	
AB		**1MG**	**N40326 002**	APR 21, 1999	
AB		**2MG**	**N40326 003**	APR 21, 1999	
> ADD >	**INNOFEM**				
> ADD > **AB**	NOVO NORDISK	**0.5MG**	**N40312 001**	NOV 19, 1999	

ESTRADIOL

TABLET; ORAL

> ADD >		INNOFEM			
> ADD >	AB	NOVO NORDISK	1MG	N40312 002	NOV 19, 1999
> ADD >	AB		2MG	N40312 003	NOV 19, 1999

TABLET; VAGINAL

		VAGIFEM		
	+	NOVO NORDISK	25 UGM	N20908 001 MAR 26, 1999

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

		ORTHO-PREFEST		
	+	JOHNSON RW	1MG,1MG;0.09MG,N/A	N21040 001 OCT 22, 1999

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

		CENESTIN		
		DURAMED	0.9MG	N20992 003 MAR 24, 1999
			0.625MG	N20992 002 MAR 24, 1999
	+		0.9MG	N20992 003 MAR 24, 1999

ESTRONE

INJECTABLE; INJECTION

		NATURAL ESTROGENIC SUBSTANCE-ESTRONE		
	+	STERIS	2MG/ML	N85237 001 NOV 23, 1982
	@		2MG/ML	N85237 001 NOV 23, 1982

ESTROPIPATE

CREAM; VAGINAL

		OGEN		
	+	ABBOTT	1.5MG/GM	N84710 001

ESTROPIPATE

CREAM; VAGINAL

		OGEN		
	+	PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001

TABLET; ORAL

		ESTROPIPATE		
> ADD >	AB	DURAMED	0.75MG	N40296 001 NOV 01, 1999
> ADD >	AB		1.5MG	N40296 002 NOV 01, 1999
> ADD >	AB		3MG	N40296 003 NOV 01, 1999
	AB	MYLAN	0.75MG	N40359 001 AUG 26, 1999
	AB		1.5MG	N40359 002 AUG 26, 1999
	AB		3MG	N40359 003 AUG 26, 1999
		OGEN .625		
	AB	ABBOTT	0.75MG	N83220 001
	AB	PHARMACIA AND UPJOHN	0.75MG	N83220 001
		OGEN 1.25		
	AB	ABBOTT	1.5MG	N83220 002
	AB	PHARMACIA AND UPJOHN	1.5MG	N83220 002
		OGEN 2.5		
	AB	+ ABBOTT	3MG	N83220 003
	AB	+ PHARMACIA AND UPJOHN	3MG	N83220 003
		OGEN 5		
	AB	ABBOTT	6MG	N83220 004
	AB	PHARMACIA AND UPJOHN	6MG	N83220 004

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

> ADD >		ETHAMBUTOL HCL		
> ADD >	AB	WEST WARD	100MG	N75095 001 NOV 30, 1999
> ADD >	AB		400MG	N75095 002 NOV 30, 1999
		MYAMBUTOL		
> ADD >	AB	LEDERLE	100MG	N16320 001
> ADD >	AB	+	400MG	N16320 003
> DLT >			100MG	N16320 001
> DLT >		+	400MG	N16320 003

ETHCHLORVYNOL

CAPSULE; ORAL

	ETHCHLORVYNOL			
AA	BANNER PHARMACAPS	200MG		N84463 002
AA		500MG		N84463 003
AA		750MG		N84463 004
@		100MG		N84463 001
@		200MG		N84463 002
@		500MG		N84463 003
@		750MG		N84463 004
	PLACIDYL			
AA +	ABBOTT	200MG		N10021 007
AA +		500MG		N10021 002
AA +		750MG		N10021 010
+		200MG		N10021 007
+		500MG		N10021 002
+		750MG		N10021 010

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE			
	BERLEX LABS	0.02MG;0.1MG		N20860 001 JUL 13, 1998
+		0.02MG;0.1MG		N20860 001 JUL 13, 1998

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	SEARLE	0.035MG;0.5MG		N17566 001
AB	WATSON LABS	0.035MG;0.5MG		N17566 001
	NORINYL 1+35 21-DAY			
AB	SEARLE	0.035MG;1MG		N17565 001
AB	WATSON LABS	0.035MG;1MG		N17565 001
	TRI-NORINYL 21-DAY			
+	SEARLE	0.035MG,0.035MG;0.5MG,1MG		N18977 001 APR 13, 1984
+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		N18977 001 APR 13, 1984

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	SEARLE	0.035MG;0.5MG		N17743 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	WATSON LABS	0.035MG;0.5MG		N17743 001
	NORINYL 1+35 28-DAY			
AB	SEARLE	0.035MG;1MG		N17565 002
AB	WATSON LABS	0.035MG;1MG		N17565 002
	TRI-NORINYL 28-DAY			
	SEARLE	0.035MG,0.035MG;0.5MG,1MG		N18977 002 APR 13, 1984
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		N18977 002 APR 13, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT			
+	PARKE DAVIS	0.005MG;1MG		N21065 002 OCT 15, 1999

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	LO/OVRAL			
AB +	WYETH AYERST	0.03MG;0.3MG		N17612 001
+		0.03MG;0.3MG		N17612 001
	LOW-OGESTREL-21			
AB	SCS	0.03MG;0.3MG		N75288 001 JUL 28, 1999
AB	WATSON LABS	0.03MG;0.3MG		N75288 001 JUL 28, 1999

TABLET; ORAL-28

	LO/OVRAL-28			
AB	WYETH AYERST	0.03MG;0.3MG		N17802 001
		0.03MG;0.3MG		N17802 001
	LOW-OGESTREL-28			
AB	SCS	0.03MG;0.3MG		N75288 002 JUL 28, 1999
AB	WATSON LABS	0.03MG;0.3MG		N75288 002 JUL 28, 1999

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	NOVOPHARM NC	200MG	N75126 001	SEP 16, 1999
AB		300MG	N75126 002	SEP 16, 1999

TABLET; ORAL
ETODOLAC

AB	EON	500MG	N74903 002	APR 19, 1999
AB	NOVOPHARM	400MG	N74847 001	APR 23, 1999
AB		500MG	N74847 002	APR 23, 1999

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	AM PHARM PARTNERS	20MG/ML	N74983 001	SEP 30, 1998
AP	APPLIED ANAL	20MG/ML	N74983 001	SEP 30, 1998
AP	STERIS	20MG/ML	N74228 001	OCT 15, 1996
@		20MG/ML	N74228 001	OCT 15, 1996

VEPESID

AP	+ BRISTOL	20MG/ML	N18768 001	NOV 10, 1983
AP	+ BRISTOL MYERS SQUIBB	20MG/ML	N18768 001	NOV 10, 1983

ETRETINATE

CAPSULE; ORAL
TEGISON

	ROCHE	10MG	N19369 001	SEP 30, 1986
+		25MG	N19369 002	SEP 30, 1986
@		10MG	N19369 001	SEP 30, 1986

ETRETINATE

CAPSULE; ORAL
TEGISON

@	ROCHE	25MG	N19369 002 SEP 30, 1986

EXEMESTANE

TABLET; ORAL
AROMASIN

+	PHARMACIA AND UPJOHN	25MG	N20753 001 OCT 21, 1999

FENOFIBRATE

CAPSULE; ORAL
TRICOR (MICRONIZED)

+	ABBOTT	67MG	N19304 002 FEB 09, 1998
		67MG	N19304 002 FEB 09, 1998
		134MG	N19304 003 JUN 30, 1999
+		200MG	N19304 004 JUN 30, 1999

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION
FERRLECIT

+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

FLUOCINONIDE

OINTMENT; TOPICAL
FLUOCINONIDE

AB	TARO	0.05%	N75008 001 JUN 30, 1999

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	BIGMAR	50MG/ML	N40291 001 MAR 24, 1999
AP	SMITH AND NEPHEW	50MG/ML	N88767 001 DEC 28, 1984
AP		50MG/ML	N89434 001 MAR 26, 1987
	@	50MG/ML	N88767 001 DEC 28, 1984
	@	50MG/ML	N89434 001 MAR 26, 1987

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC

+	LILLY	EQ 20MG BASE	N18936 001 DEC 29, 1987
		EQ 20MG BASE	N18936 001 DEC 29, 1987
+		EQ 40MG BASE	N18936 003 JUN 15, 1999
	@	EQ 60MG BASE	N18936 004 JUN 15, 1999

TABLET; ORAL
PROZAC

	LILLY	EQ 10MG BASE	N20974 001 MAR 09, 1999
+		EQ 20MG BASE	N20974 002 MAR 09, 1999
+		EQ 10MG BASE	N20974 001 MAR 09, 1999
	@	EQ 20MG BASE	N20974 002 MAR 09, 1999

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA	VINTAGE PHARMS	1MG	N86296 001
	@	1MG	N86296 001

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP	ABBOTT	10MG/ML	N75241 001 MAY 28, 1999
AP	SMITH AND NEPHEW	10MG/ML	N70078 001 FEB 05, 1986
	@	10MG/ML	N70078 001 FEB 05, 1986
AP	STERIS	10MG/ML	N70019 001 SEP 22, 1986
AP		10MG/ML	N70604 001 JAN 02, 1987
	@	10MG/ML	N70019 001 SEP 22, 1986
	@	10MG/ML	N70604 001 JAN 02, 1987

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL

+	DAVIS AND GECK	20MG/ML	N07842 001
+		100MG/ML	N07842 002
	@	20MG/ML	N07842 001
	@	100MG/ML	N07842 002

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

+	SOLOPAK	25MG/ML	N19961 002 JAN 17, 1991
	@	25MG/ML	N19961 002 JAN 17, 1991

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON

+	ORGANON INC	EQ 250 UGM BASE/0.5ML	N21057 001 JUL 29, 1999

GEMFIBROZIL

TABLET; ORAL

	GEMFIBROZIL			
AB	PUREPAC PHARM	**600MG**	**N74360 001**	**AUG 31, 1994**
@		600MG	N74360 001	AUG 31, 1994

GENTAMICIN SULFATE

INJECTABLE; INJECTION

	APOGEN			
AP	KING PHARMS	**EQ 10MG BASE/ML**	**N62289 001**	
AP		**EQ 40MG BASE/ML**	**N62289 002**	
@		EQ 10MG BASE/ML	N62289 001	
@		EQ 40MG BASE/ML	N62289 002	
	BRISTAGEN			
AP	BRISTOL	**EQ 40MG BASE/ML**	**N62288 001**	
@		EQ 40MG BASE/ML	N62288 001	
	GENTAMICIN SULFATE			
AP	SOLOPAK	**EQ 10MG BASE/ML**	**N62507 001**	**JUN 06, 1985**
AP		**EQ 40MG BASE/ML**	**N62507 002**	**JUN 06, 1985**
@		EQ 10MG BASE/ML	N62507 001	JUN 06, 1985
@		EQ 40MG BASE/ML	N62507 002	JUN 06, 1985

SOLUTION/DROPS; OPHTHALMIC

	GENTAMICIN SULFATE			
AT	ALCON	**EQ 0.3% BASE**	**N62196 001**	
AT	FALCON PHARMS	**EQ 0.3% BASE**	**N62196 001**	

GLIPIZIDE

TABLET; ORAL

	GLUCOTROL			
	PFIZER	2.5MG	N17783 003	MAY 11, 1993
@		2.5MG	N17783 003	MAY 11, 1993

TABLET, EXTENDED RELEASE; ORAL

	GLUCOTROL XL			
+	PFIZER	2.5MG	N20329 003	AUG 10, 1999

GLYBURIDE

TABLET; ORAL

	GLYBURIDE (MICRONIZED)			
AB	MOVA	**4.5MG**	**N74591 003**	**DEC 22, 1997**
		4.5MG	N74591 003	DEC 22, 1997
AB	MYLAN	**6MG**	**N74792 003**	**AUG 17, 1999**
AB	NOVOPHARM	**1.5MG**	**N74686 001**	**APR 20, 1999**
AB		**3MG**	**N74686 002**	**APR 20, 1999**
AB		**4.5MG**	**N74686 003**	**APR 20, 1999**
AB		**6MG**	**N74686 004**	**APR 20, 1999**

GLYCOPYRROLATE

INJECTABLE; INJECTION

	GLYCOPYRROLATE			
AP	STERIS	**0.2MG/ML**	**N86947 001**	**JUN 24, 1983**
@		0.2MG/ML	N86947 001	JUN 24, 1983

TABLET; ORAL

	ROBINUL		
+	HORIZON PHARM	1MG	N12827 001
+	ROBINS AH	1MG	N12827 001
	ROBINUL FORTE		
+	HORIZON PHARM	2MG	N12827 002
+	ROBINS AH	2MG	N12827 002

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			
AT	STERIS	**0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML**	**N62788 001**	**JUN 11, 1987**
@		0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001	JUN 11, 1987

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	SCS	0.5MG	N70720 001 JUN 10, 1986
AB		1MG	N70721 001 JUN 10, 1986
AB		2MG	N70722 001 JUN 10, 1986
AB		5MG	N70723 001 JUN 10, 1986
AB		10MG	N70724 001 JUN 10, 1986
AB		20MG	N70725 001 SEP 24, 1986
@		0.5MG	N70720 001 JUN 10, 1986
@		1MG	N70721 001 JUN 10, 1986
@		2MG	N70722 001 JUN 10, 1986
@		5MG	N70723 001 JUN 10, 1986
@		10MG	N70724 001 JUN 10, 1986
@		20MG	N70725 001 SEP 24, 1986

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001 MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002 MAY 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

AA	SCS	EQ 2MG BASE/ML	N70726 001 JUN 10, 1986
@		EQ 2MG BASE/ML	N70726 001 JUN 10, 1986

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
AP	STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988
@		EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
@		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	SMITH AND NEPHEW	10 UNITS/ML	N88458 001 JUL 26, 1984
AP		10 UNITS/ML	N88580 001 OCT 25, 1984
AP		100 UNITS/ML	N88460 001 JUL 26, 1984
AP		100 UNITS/ML	N88581 001 OCT 25, 1984
@		10 UNITS/ML	N88458 001 JUL 26, 1984
@		10 UNITS/ML	N88580 001 OCT 25, 1984
@		100 UNITS/ML	N88460 001 JUL 26, 1984
@		100 UNITS/ML	N88581 001 OCT 25, 1984
AP	SOLOPAK	100 UNITS/ML	N88459 001 JUL 26, 1984
@		100 UNITS/ML	N88459 001 JUL 26, 1984

HEPARIN SODIUM

AP	SMITH AND NEPHEW	1,000 UNITS/ML	N88239 001 JUL 26, 1984

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

	@	SMITH AND NEPHEW	1,000 UNITS/ML	N88239 001 JUL 26, 1984

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		HALSEY	1.5MG/5ML;5MG/5ML	N40285 001 JUL 19, 1999

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL

AP	+	LUITPOLD	20MG/ML	N40136 001 JUN 30, 1997
	+		20MG/ML	N40136 001 JUN 30, 1997
AP		SOLOPAK	20MG/ML	N88517 001 AUG 22, 1985
	@		20MG/ML	N88517 001 AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

AB		SOLVAY	25MG;25MG	N87608 001 FEB 08, 1982
AB			50MG;50MG	N87213 001 FEB 08, 1982
	@		25MG;25MG	N87608 001 FEB 08, 1982
	@		50MG;50MG	N87213 001 FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

BP		SOLVAY	25MG;15MG;0.1MG	N88376 001 OCT 28, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

	@	SOLVAY	25MG;15MG;0.1MG	N88376 001 OCT 28, 1983

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB		MAST MM	25MG	N86192 001
AB			50MG	N86192 002
	@		25MG	N86192 001
	@		50MG	N86192 002

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

	@	SANOFI SYNTHELABO	12.5MG;75MG	N20758 001 SEP 30, 1997
			12.5MG;150MG	N20758 002 SEP 30, 1997
	+		12.5MG;300MG	N20758 003 AUG 31, 1998

AVAPRO HCT

	@	SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
	+		12.5MG;150MG	N20758 002 SEP 30, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		DURAMED	25MG;37.5MG	N75052 001 JUN 18, 1999

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT		G AND W LABS	1%	N84059 001
	@		1%	N84059 001

HYDROCORTISONE

ENEMA; RECTAL

		CORTENEMA		
AB	+	SOLVAY	**100MG/60ML**	**N16199 001**
BR	+		100MG/60ML	N16199 001
		HYDROCORTISONE		
AB		COPLEY PHARM	**100MG/60ML**	**N74171 001** MAY 27, 1994
BR			100MG/60ML	N74171 001 MAY 27, 1994

LOTION; TOPICAL

		DERMACORT		
AT		SOLVAY	**0.5%**	**N84573 002**
AT			**1%**	**N86462 001**
	@		0.5%	N84573 002
	@		1%	N86462 001
		HYDROCORTISONE		
AT		THAMES	**2.5%**	**N40247 001** JUL 23, 1999

SOLUTION; TOPICAL

		TEXACORT		
AT	+	BIOGLAN PHAR	**1%**	**N80425 001**
	+		2.5%	N81271 001 APR 17, 1992
	+	GENDERM	2.5%	N81271 001 APR 17, 1992
AT	+	MEDICIS	**1%**	**N80425 001**

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

			NEO-OTOSOL-HC		
> ADD >	**AT**		ALCON	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62423 001** AUG 25, 1983
> ADD >					
> ADD >					
> DLT >	**AT**		STERIS	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62423 001** AUG 25, 1983
> DLT >					
> DLT >					

HYDROCORTISONE ACETATE

CREAM; TOPICAL

		HYDROCORTISONE ACETATE		
	+	FERNDALE LABS	2.5%	N40259 001 JUL 29, 1999

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

		HYDROCORTISONE SODIUM SUCCINATE		
AP		STERIS	**EQ 100MG BASE/VIAL**	**N84737 002**
AP			**EQ 100MG BASE/VIAL**	**N84738 001**
AP			**EQ 250MG BASE/VIAL**	**N84737 001**
AP			**EQ 500MG BASE/VIAL**	**N84747 001**
AP			**EQ 1GM BASE/VIAL**	**N84748 001**
	@		EQ 100MG BASE/VIAL	N84737 002
	@		EQ 100MG BASE/VIAL	N84738 001
	@		EQ 250MG BASE/VIAL	N84737 001
	@		EQ 500MG BASE/VIAL	N84747 001
	@		EQ 1GM BASE/VIAL	N84748 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

		PAREDRINE		
	+	AKORN	1%	N00004 004
	+	PHARMICS	1%	N00004 004

HYDROXYUREA

CAPSULE; ORAL

		HYDROXYUREA		
AB		PAR PHARM	**500MG**	**N75340 001** FEB 24, 1999

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDROXYZINE HCL		
AP		SOLOPAK	**25MG/ML**	**N87591 001**
AP			**50MG/ML**	**N87593 001**
AP			**50MG/ML**	**N87595 001**
	@		25MG/ML	N87591 001
	@		50MG/ML	N87593 001
	@		50MG/ML	N87595 001

IBUPROFEN

SUSPENSION; ORAL

		MOTRIN		
AB	+	MCNEIL	**100MG/5ML**	**N19842 001** SEP 19, 1989

IBUPROFEN

SUSPENSION; ORAL

		MOTRIN		
AB	+	MCNEIL CONS	100MG/5ML	N19842 001 SEP 19, 1989

TABLET; ORAL

		IBUPROFEN		
AB		NORTON HN	400MG	N71145 001 SEP 23, 1986
AB			600MG	N71146 001 SEP 23, 1986
AB			800MG	N71769 001 MAY 08, 1987
AB		ZENITH GOLDLINE	400MG	N71145 001 SEP 23, 1986
AB			600MG	N71146 001 SEP 23, 1986
AB			800MG	N71769 001 MAY 08, 1987
		MOTRIN		
AB		MCNEIL	300MG	N17463 003
AB			400MG	N17463 002
AB			600MG	N17463 004
AB	+		800MG	N17463 005 MAY 22, 1985
			100MG	N20418 001 NOV 16, 1994
AB		MCNEIL CONS	300MG	N17463 003
AB			400MG	N17463 002
AB			600MG	N17463 004
AB	+		800MG	N17463 005 MAY 22, 1985
			100MG	N20418 001 NOV 16, 1994

TABLET, CHEWABLE; ORAL

		MOTRIN		
		MCNEIL	50MG	N20135 001 NOV 16, 1994
	+		100MG	N20135 002 NOV 16, 1994
		MCNEIL CONS	50MG	N20135 001 NOV 16, 1994
	+		100MG	N20135 002 NOV 16, 1994

IMIGLUCERASE

INJECTABLE; INJECTION

		CEREZYME		
	+	GENZYME	200 UNITS/VIAL	N20367 001 MAY 23, 1994
			200 UNITS/VIAL	N20367 001 MAY 23, 1994
	+		400 UNITS/VIAL	N20367 002 SEP 22, 1999

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

		INDOCIN SR		
AB		EON	75MG	N74464 001 MAY 28, 1998
AB	+		75MG	N74464 001 MAY 28, 1998
AB	+	MERCK	75MG	N18185 001 FEB 23, 1982
	@		75MG	N18185 001 FEB 23, 1982

INSULIN HUMAN

INJECTABLE; INJECTION

		VELOSULIN BR		
	+	NOVO NORDISK	100 UNITS/ML	N21028 001 JUL 19, 1999

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

		RENOVUE-65		
	+	BRACCO	65%	N17902 001
	@		65%	N17902 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

		IPRATROPIUM BROMIDE		
AN		ALPHARMA	0.02%	N75111 001 APR 22, 1999

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	ISOETHARINE HCL			
AN	INTL MEDICATION	0.08%	N86651 002	
AN		0.1%	N86651 003	
AN	+	0.1%	N86651 003	
AN		0.167%	N86651 005	
AN	+	0.167%	N86651 005	
AN		0.25%	N86651 007	
AN	+	0.25%	N86651 007	
	+	0.08%	N86651 002	
	ISOETHARINE HCL S/F			
AN	+ DEY	0.08%	N89817 001	NOV 22, 1988
AN	+	0.1%	N89818 001	NOV 22, 1988
AN	+	0.17%	N89819 001	NOV 22, 1988
AN	+	0.25%	N89820 001	NOV 22, 1988
	@	0.08%	N89817 001	NOV 22, 1988
	@	0.1%	N89818 001	NOV 22, 1988
	@	0.17%	N89819 001	NOV 22, 1988
	@	0.25%	N89820 001	NOV 22, 1988

ISOFLURANE

LIQUID; INHALATION

	FORANE			
AN	+ BAXTER PHARM PROD	99.9%	N17624 001	
AN	+ OHMEDA	99.9%	N17624 001	
	ISOFLURANE			
AN	HALOCARBON PRODS	99.9%	N75225 001	OCT 20, 1999

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

	RIFAMATE			
	+ DOW PHARM	150MG;300MG	N61884 001	
	+ HOECHST MARION RSSL	150MG;300MG	N61884 001	

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE			
AB	ZENECA	30MG	N88124 001	AUG 21, 1990
	@	30MG	N88124 001	AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE MONONITRATE			
AB	BRIGHTSTONE	60MG	N75166 001	OCT 07, 1999

ISOTRETINOIN

CAPSULE; ORAL

	ACCUTANE			
	HLR	10MG	N18662 002	MAY 07, 1982
		20MG	N18662 004	MAR 28, 1983
	+	40MG	N18662 003	MAY 07, 1982
	ROCHE	10MG	N18662 002	MAY 07, 1982
		20MG	N18662 004	MAR 28, 1983
	+	40MG	N18662 003	MAY 07, 1982

ITRACONAZOLE

INJECTABLE; INJECTION

	SPORANOX			
	+ JANSSEN	10MG/ML	N20966 001	MAR 30, 1999

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN SULFATE			
AP	SOLOPAK	EQ 75MG BASE/2ML	N62605 003	FEB 26, 1986

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN SULFATE				
AP	SOLOPAK	**EQ 500MG BASE/2ML**	**N62605 001**		
			FEB 26, 1986		
AP		**EQ 1GM BASE/3ML**	**N62605 002**		
			FEB 26, 1986		
	@	EQ 75MG BASE/2ML	N62605 003		
			FEB 26, 1986		
	@	EQ 500MG BASE/2ML	N62605 001		
			FEB 26, 1986		
	@	EQ 1GM BASE/3ML	N62605 002		
			FEB 26, 1986		

KETOCONAZOLE

TABLET; ORAL

	KETOCONAZOLE				
AB	APPLIED ANAL	200MG	**N75341 001**	> ADD >	
			JUL 27, 1999	> ADD >	
AB	MUTUAL PHARMA	200MG	**N75314 001**	> ADD >	
			JUN 15, 1999	> ADD >	
AB	NOVOPHARM	200MG	**N74971 001**		
			JUN 15, 1999		
AB	SIDMAK LABS CA	200MG	**N75362 001**		
			JUN 15, 1999		
AB	TARO	200MG	**N75319 001**		
			JUN 15, 1999		
AB	TEVA	200MG	**N75273 001**		
			JUN 15, 1999		
	NIZORAL				
AB	+ JANSSEN	200MG	**N18533 001**		
	+	200MG	N18533 001		

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN		
AB	ANDRX PHARMS	100MG	**N75270 002**
			MAR 24, 1999
AB		150MG	**N75270 003**
			MAR 24, 1999
AB		200MG	**N75270 001**
			MAR 24, 1999
	ORUVAIL		
AB	WYETH AYERST	100MG	**N19816 003**
			FEB 08, 1995

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	ORUVAIL		
AB	WYETH AYERST	150MG	**N19816 002**
			FEB 08, 1995
		100MG	N19816 003
			FEB 08, 1995
		150MG	N19816 002
			FEB 08, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE		
AP	ABBOTT	15MG/ML	**N74993 001**
			JAN 27, 1999
AP		30MG/ML	**N74993 002**
			JAN 27, 1999
AP	BAXTER PHARM PROD	15MG/ML	**N75299 001**
			NOV 03, 1999
AP		30MG/ML	**N75299 002**
			NOV 03, 1999
AP	BEDFORD	15MG/ML	**N75222 001**
			APR 26, 1999
AP		15MG/ML	**N75230 002**
			OCT 25, 1999
AP		30MG/ML	**N75222 002**
			APR 26, 1999
AP		30MG/ML	**N75228 001**
			APR 26, 1999
AP		30MG/ML	**N75230 001**
			OCT 25, 1999

SOLUTION/DROPS; OPHTHALMIC

	ACULAR		
	+ ALLERGAN	0.5%	N19700 001
			NOV 09, 1992
	+ SYNTEX	0.5%	N19700 001
			NOV 09, 1992

TABLET; ORAL

	KETOROLAC TROMETHAMINE		
AB	SIDMAK LABS CA	10MG	**N75284 001**
			JUN 23, 1999

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

	ZADITOR			
+	CIBA	EQ 0.025% BASE		N21066 001 JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

		LABETALOL HCL		
> ADD >	**AP**	ABBOTT	**5MG/ML**	**N75239 001** NOV 29, 1999
> ADD >				
> ADD >	**AP**		**5MG/ML**	**N75240 001** NOV 29, 1999
> ADD >				
> ADD >	**AP**	APOTHECON	**5MG/ML**	**N75355 001** NOV 29, 1999
> ADD >				
	AP	BEDFORD	**5MG/ML**	**N75303 001** MAY 28, 1999
	AP	FAULDING	**5MG/ML**	**N75242 001** SEP 30, 1999
> ADD >	**AP**	TAYLOR	**5MG/ML**	**N75431 001** NOV 29, 1999
> ADD >				
> ADD >	**AP**		**5MG/ML**	**N75524 001** NOV 29, 1999
> ADD >				

TABLET; ORAL

		LABETALOL HCL		
AB		MUTUAL PHARM	**100MG**	**N75215 001** JUL 29, 1999
AB			**200MG**	**N75215 002** JUL 29, 1999
AB			**300MG**	**N75215 003** JUL 29, 1999
		TRANDATE		
AB		FARO PHARMS	**100MG**	**N18716 001** MAY 24, 1985
AB			**200MG**	**N18716 002** AUG 01, 1984
AB			**300MG**	**N18716 003** AUG 01, 1984
	@		400MG	N18716 004 AUG 01, 1984
AB		GLAXO WELLCOME	**100MG**	**N18716 001** MAY 24, 1985
AB			**200MG**	**N18716 002** AUG 01, 1984

LABETALOL HYDROCHLORIDE

TABLET; ORAL

		TRANDATE		
AB		GLAXO WELLCOME	**300MG**	**N18716 003** AUG 01, 1984
	@		400MG	N18716 004 AUG 01, 1984

LACTULOSE

SOLUTION; ORAL

		LACTULOSE		
AA		PACO	**10GM/15ML**	**N73160 001** AUG 25, 1992
	@		10GM/15ML	N73160 001 AUG 25, 1992

SOLUTION; ORAL, RECTAL

		LACTULOSE		
AA		PACO	**10GM/15ML**	**N72029 001** AUG 25, 1992
	@		10GM/15ML	N72029 001 AUG 25, 1992

LAMIVUDINE

SOLUTION; ORAL

		EPIVIR-HBV		
+		GLAXO WELLCOME	5MG/ML	N20596 002 DEC 08, 1998
			5MG/ML	N20596 002 DEC 08, 1998
+			5MG/ML	N21004 001 DEC 08, 1998

TABLET; ORAL

		EPIVIR-HBV		
+		GLAXO WELLCOME	100MG	N20564 002 DEC 08, 1998
			100MG	N20564 002 DEC 08, 1998
+			100MG	N21003 001 DEC 08, 1998

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	+	ABBOTT	EQ 10MG BASE/ML	N40147 001	> ADD >
				JUN 25, 1997	> ADD >
AP	+	BEDFORD	EQ 200MG BASE/VIAL	N40056 001	> ADD >
				MAY 23, 1995	> ADD >

LEUCOVORIN CALCIUM PRESERVATIVE FREE

	+	ABBOTT	EQ 10MG BASE/ML	N40147 001	> ADD >
				JUN 25, 1997	> ADD >
AP	+	BEDFORD	EQ 200MG BASE/VIAL	N40056 001	> ADD >
				MAY 23, 1995	> ADD >
AP		BIGMAR	EQ 10MG BASE/ML	N40286 001	> ADD >
				FEB 26, 1999	> ADD >
AP			EQ 200MG BASE/VIAL	N40258 001	> ADD >
				FEB 26, 1999	> ADD >
	+		EQ 500MG BASE/VIAL	N40286 001	> ADD >
				FEB 26, 1999	> ADD >
AP		GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N40332 001	> ADD >
				JUN 28, 1999	> ADD >

TABLET; ORAL
LEUCOVORIN CALCIUM

AB		INVAMED	EQ 15MG BASE	N75327 001
				MAR 24, 1999

WELLCOVORIN

AB		GLAXO WELLCOME	EQ 5MG BASE	N18342 001
				JUL 08, 1983
AB	+		EQ 25MG BASE	N18342 002
				JUL 08, 1983
	@		EQ 5MG BASE	N18342 001
				JUL 08, 1983
	@		EQ 25MG BASE	N18342 002
				JUL 08, 1983

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
XOPENEX

	+	SEPRACOR	EQ 0.021% BASE	N20837 001
				MAR 25, 1999
	+		EQ 0.042% BASE	N20837 002
				MAR 25, 1999

LEVETIRACETAM

TABLET; ORAL
KEPPRA

		UCB	250MG	N21035 001
				NOV 30, 1999
			500MG	N21035 002
				NOV 30, 1999
	+		750MG	N21035 003
				NOV 30, 1999

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE

		DARWIN DISCOVERY	EQ 2.5MG BASE/ML	N20997 001
				AUG 05, 1999
			EQ 5MG BASE/ML	N20997 002
				AUG 05, 1999
	+		EQ 7.5MG BASE/ML	N20997 003
				AUG 05, 1999

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL
ORLAAM

	+	BIODEVELOPMENT	10MG/ML	N20315 001
				JUL 09, 1993
	+	ROXANE	10MG/ML	N20315 001
				JUL 09, 1993

LEVONORGESTREL

TABLET; ORAL
PLAN B

	+	WOMENS CAPITAL	0.75MG	N21045 001
				JUL 28, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TOPICAL
LIDODERM

	+	TEIKOKU PHARMA USA	700MG/12HR	N20612 001
				MAR 19, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TRANSDERMAL
LIDODERM
+ HIND HLTHCARE — 700MG/12HR — N20612 001 MAR 19, 1999

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA
+ ASTRA PHARMS — 2.5%;2.5% — N20962 001 FEB 04, 1998

DISC; TOPICAL
EMLA
+ ASTRAZENECA — 2.5%;2.5% — N20962 001 FEB 04, 1998

LINDANE

CREAM; TOPICAL
KWELL
+ REED AND CARNRICK — 1% — N84218 001
@ — 1% — N84218 001

LOTION; TOPICAL
KWELL
AT + REED AND CARNRICK — 1% — N84218 002
@ — 1% — N84218 002

LINDANE
AT ALPHARMA — 1% — N87313 001
AT + — 1% — N87313 001

SHAMPOO; TOPICAL
KWELL
AT + REED AND CARNRICK — 1% — N84219 001
@ — 1% — N84219 001

LINDANE
AT ALPHARMA — 1% — N87266 001
AT + — 1% — N87266 001

LISINOPRIL

TABLET; ORAL
ZESTRIL
ZENECA — 30MG — N19777 006 JAN 20, 1999

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE
AB SOLVAY — 300MG — N16782 001
@ — 300MG — N16782 001

TABLET; ORAL
LITHIUM CARBONATE
AB PFIZER — 300MG — N16834 001
AB + — 300MG — N16834 001

LITHOTABS
AB + SOLVAY — 300MG — N16980 001
@ — 300MG — N16980 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM
AB + JANSSEN — 2MG — N17694 001
® — 2MG — N17690 001
AB + MCNEIL CONS — 2MG — N17694 001
@ — 2MG — N17690 001

LORACARBEF

CAPSULE; ORAL
LORABID
KING PHARMS — 200MG — N50668 001 DEC 31, 1991
+ — 400MG — N50668 002 APR 05, 1996
LILLY — 200MG — N50668 001 DEC 31, 1991
+ — 400MG — N50668 002 APR 05, 1996

POWDER FOR RECONSTITUTION; ORAL
LORABID
KING PHARMS — 100MG/5ML — N50667 001 DEC 31, 1991

LORACARBEF

POWDER FOR RECONSTITUTION; ORAL
LORABID

+	KING PHARMS	200MG/5ML	N50667 002 DEC 31, 1991
	LILLY	100MG/5ML	N50667 001 DEC 31, 1991
+		200MG/5ML	N50667 002 DEC 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
LOTEMAX

+	PHARMOS	0.5%	N20841 001 MAR 09, 1998
@		0.5%	N20841 001 MAR 09, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001 APR 04, 1984
@		30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001 APR 04, 1984

MALATHION

LOTION; TOPICAL
OVIDE

@	MEDICIS	0.5%	N18613 001 AUG 02, 1982
+		0.5%	N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%

AP		STERIS	12.5GM/50ML	N87460 001 JUN 27, 1983
	@		12.5GM/50ML	N87460 001 JUN 27, 1983

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
VERMOX

AB	+	JANSSEN	100MG	N17481 001
AB	+	MCNEIL CONS	100MG	N17481 001

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL
MECLAN

+	JOHNSON AND JOHNSON	1%	N50518 001
@		1%	N50518 001

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
CYCRIN

	ESI	2.5MG	N81239 001 OCT 30, 1992
		5MG	N81240 001 OCT 30, 1992
		10MG	N89386 001 SEP 09, 1987
@		2.5MG	N81239 001 OCT 30, 1992
@		5MG	N81240 001 OCT 30, 1992
@		10MG	N89386 001 SEP 09, 1987

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
REPRONEX

BX	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001 AUG 27, 1999

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	REPRONEX			
BX	FERRING	150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DEMEROL			
AP	+ ABBOTT	25MG/ML	N05010 007	
AP	+	50MG/ML	N05010 002	
AP	+	75MG/ML	N05010 009	
AP	+	100MG/ML	N05010 003	
AP	+ SANOFI SYNTHELABO	25MG/ML	N05010 007	
AP	+	50MG/ML	N05010 002	
AP	+	75MG/ML	N05010 009	
AP	+	100MG/ML	N05010 003	
	MEPERIDINE HCL			
AP	+ ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
AP	ASTRA PHARMS	10MG/ML	N81002 001	JUL 30, 1993
AP	INTL MEDICATION	10MG/ML	N81309 001	AUG 30, 1993
AP	MALLINCKRODT	10MG/ML	N40163 001	MAY 12, 1997
AP	STERIS	10MG/ML	N73443 001	MAR 17, 1992
	MEPERIDINE HCL PRESERVATIVE FREE			
AP	+ ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
AP	ASTRA PHARMS	10MG/ML	N81002 001	JUL 30, 1993
AP	FAULDING	10MG/ML	N40305 001	MAR 10, 1999
AP	INTL MEDICATION	10MG/ML	N81309 001	AUG 30, 1993
AP	MALLINCKRODT	10MG/ML	N40163 001	MAY 12, 1997
AP	STERIS	10MG/ML	N73443 001	MAR 17, 1992

SYRUP; ORAL

	DEMEROL			
AA	+ ABBOTT	50MG/5ML	N05010 005	
AA	+ SANOFI SYNTHELABO	50MG/5ML	N05010 005	

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

	DEMEROL			
AA	+ ABBOTT	50MG	N05010 001	
AA	+	100MG	N05010 004	
AA	+ SANOFI SYNTHELABO	50MG	N05010 001	
AA	+	100MG	N05010 004	
	MEPERIDINE HCL			
AA	AMIDE PHARM	50MG	N40331 001	MAY 28, 1999
AA		100MG	N40331 002	MAY 28, 1999
AA	DURAMED	50MG	N40318 001	OCT 05, 1999
AA		100MG	N40318 002	OCT 05, 1999

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE			
AA	PHARMAVITE	400MG	N84438 001	
Ⓐ		400MG	N84438 001	

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

	MERSALYL-THEOPHYLLINE		
+	STERIS	100MG/ML;50MG/ML	N84875 001
Ⓐ		100MG/ML;50MG/ML	N84875 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
+	BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995
		625MG	N20357 003	NOV 05, 1998
		750MG	N20357 004	NOV 05, 1998
		500MG	N20357 001	MAR 03, 1995
Ⓐ		625MG	N20357 003	NOV 05, 1998

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE
@ BRISTOL MYERS SQUIBB 750MG — N20357 004 NOV 05, 1998

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE

AP	BIGMAR	EQ 25MG BASE/ML	N40263 001 FEB 26, 1999

METHOTREXATE PRESERVATIVE FREE

AP	BIGMAR	EQ 25MG BASE/ML	N40265 001 FEB 26, 1999
AP		EQ 1GM BASE/VIAL	N40266 001 FEB 26, 1999

METHOTREXATE SODIUM

+	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

AP +	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

TABLET; ORAL
METHOTREXATE SODIUM

AB	DURAMED	EQ 2.5MG BASE	N40233 001 JUN 17, 1999

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

+	IMMUNEX	20MG/ML	N15865 001
@		20MG/ML	N15865 001

METHOXSALEN

INJECTABLE; INJECTION
UVADEX

+	THERAKOS	0.02MG/ML	N20969 001 FEB 25, 1999

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	SMITH AND NEPHEW	50MG/ML	N70841 001 JAN 02, 1987
@		50MG/ML	N70841 001 JAN 02, 1987

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METADATE ER

	MEDEVA	10MG	N40306 001 OCT 20, 1999

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	STERIS	EQ 40MG BASE/VIAL	N86953 001 JUL 22, 1982
AP		EQ 125MG BASE/VIAL	N87030 001 JUL 22, 1982
AP		EQ 500MG BASE/VIAL	N88523 001 JUL 24, 1984
AP		EQ 1GM BASE/VIAL	N88524 001 JUL 24, 1984
@		EQ 40MG BASE/VIAL	N86953 001 JUL 22, 1982
@		EQ 125MG BASE/VIAL	N87030 001 JUL 22, 1982
@		EQ 500MG BASE/VIAL	N88523 001 JUL 24, 1984
@		EQ 1GM BASE/VIAL	N88524 001 JUL 24, 1984

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	SMITH AND NEPHEW	EQ 5MG BASE/ML	N70623 001 MAR 02, 1987
@		EQ 5MG BASE/ML	N70623 001 MAR 02, 1987

METOLAZONE

TABLET; ORAL
ZAROXOLYN
MEDEVA 2.5MG N17386 001
\+ 2.5MG N17386 001

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE
AB PUREPAC PHARM **50MG** **N74380 001 JUL 29, 1994**
AB **100MG** **N74380 002 JUL 29, 1994**
@ 50MG N74380 001 JUL 29, 1994
@ 100MG N74380 002 JUL 29, 1994

METRONIDAZOLE

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER
AP + BAXTER HLTHCARE **500MG/100ML** **N18657 001**
AP + SCS **500MG/100ML** **N18657 001**
METRONIDAZOLE
AP STERIS **500MG/100ML** **N70170 001 APR 01, 1986**
@ 500MG/100ML N70170 001 APR 01, 1986

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK
\+ ADVANCED CARE PRODS 1.2GM,2% N20968 001 JUN 30, 1999 >DLT> >DLT> >DLT> >DLT>

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
AB ALPHARMA US PHARM **200MG** **N73508 001 NOV 19, 1993** >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>
AB NMC **200MG** **N73508 001 NOV 19, 1993**

MICONAZOLE NITRATE

TAMPON; VAGINAL
MONISTAT 5
\+ ADVANCED CARE PRODS 100MG **N18592 001 OCT 27, 1989**
@ 100MG N18592 001 OCT 27, 1989

MIGLITOL

TABLET; ORAL
GLYSET
BAYER 25MG **N20682 001 DEC 18, 1996**
50MG **N20682 002 DEC 18, 1996**
\+ 100MG **N20682 003 DEC 18, 1996**
PHARMACIA AND UPJOHN 25MG N20682 001 DEC 18, 1996
50MG N20682 002 DEC 18, 1996
\+ 100MG N20682 003 DEC 18, 1996

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL
\+ DANBURY PHARMA EQ 75MG BASE N63065 002 JUN 10, 1999
AB GLOBAL PHARM **EQ 50MG BASE** **N65005 001 MAR 23, 1999**
AB **EQ 100MG BASE** **N65005 002 MAR 23, 1999**
AB WARNER CHILCOTT **EQ 50MG BASE** **N63066 001 AUG 14, 1990**
AB **EQ 100MG BASE** **N63067 001 JUL 31, 1990**
VECTRIN
AB MEDICIS **EQ 50MG BASE** **N63066 001 AUG 14, 1990**
AB **EQ 75MG BASE** **N63067 002 SEP 15, 1999**
AB **EQ 100MG BASE** **N63067 001 JUL 31, 1990**

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

			VECTRIN		
> DLT >	AB		WARNER CHILCOTT	EQ 75MG BASE	N63067 002
> DLT					SEP 15, 1999

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

			MIVACRON		
> ADD >		+	ABBOTT	EQ 2MG BASE/ML	N20098 001
> ADD >					JAN 22, 1992
> DLT >		+	GLAXO WELLCOME	EQ 2MG BASE/ML	N20098 001
> DLT >					JAN 22, 1992
			MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER		
> ADD >		+	ABBOTT	EQ 0.5MG BASE/ML	N20098 002
> ADD >					JAN 22, 1992
> ADD >		+		EQ 50MG BASE/100ML	N20098 003
> ADD >					JAN 22, 1992
> DLT >		+	GLAXO WELLCOME	EQ 0.5MG BASE/ML	N20098 002
> DLT >					JAN 22, 1992
> DLT >		+		EQ 50MG BASE/100ML	N20098 003
> DLT >					JAN 22, 1992

NADOLOL

TABLET; ORAL

		CORGARD		
AB		APOTHECON	20MG	N18063 005
				OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004
AB		BRISTOL MYERS SQUIBB	20MG	N18063 005
				OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

		NALOXONE HCL		
AP		SMITH AND NEPHEW	0.02MG/ML	N71671 001
				NOV 17, 1987
AP			0.4MG/ML	N71681 001
				NOV 17, 1987
	@		0.02MG/ML	N71671 001
				NOV 17, 1987
	@		0.4MG/ML	N71681 001
				NOV 17, 1987
AP		STERIS	0.4MG/ML	N71339 001
				NOV 18, 1987
	@		0.4MG/ML	N71339 001
				NOV 18, 1987

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

		NALTREXONE HCL		
AB		AMIDE PHARM	50MG	N75274 001
				MAY 26, 1999

NANDROLONE DECANOATE

INJECTABLE; INJECTION

		NANDROLONE DECANOATE		
AO		STERIS	50MG/ML	N88554 001
				FEB 10, 1986
	@		50MG/ML	N88554 001
				FEB 10, 1986

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

		DURABOLIN		
AO	+	ORGANON	25MG/ML	N11891 001
AO	+		50MG/ML	N11891 002
	+		25MG/ML	N11891 001
	+		50MG/ML	N11891 002
		NANDROLONE PHENPROPIONATE		
AO		STERIS	25MG/ML	N86386 001
				JUN 17, 1983
AO			50MG/ML	N87488 001
				JUN 17, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
NANDROLONE PHENPROPIONATE
@ STERIS 25MG/ML N86386 001 JUN 17, 1983
@ 50MG/ML N87488 001 JUN 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
NAPHAZOLINE HCL
AT AKORN 0.1% N83590 001
AT TAYLOR 0.1% N83590 001

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN
AB SIDMAK LABS CA 375MG N75337 001 MAY 26, 1999
AB 500MG N75337 002 MAY 26, 1999

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
AB PUREPAC PHARM EQ 250MG BASE N74319 001 MAR 20, 1995
AB EQ 500MG BASE N74319 002 MAR 20, 1995
@ EQ 250MG BASE N74319 001 MAR 20, 1995 >ADD>
@ EQ 500MG BASE N74319 002 MAR 20, 1995 >ADD>
>ADD>
>ADD>
>ADD>
>ADD>
>ADD>
>ADD>

NEDOCROMIL SODIUM

SOLUTION; INHALATION
TILADE
+ RHONE POULENC RORER 0.5% N20750 001 OCT 01, 1997

NEDOCROMIL SODIUM

SOLUTION; INHALATION
TILADE
@ RHONE POULENC RORER 0.5% N20750 001 OCT 01, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION
+ INTL MINERALS 15MG/5ML;3.75MG/5ML; 600MG/5ML N08378 003
@ 15MG/5ML;3.75MG/5ML; 600MG/5ML N08378 003

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP
+ ELAN PHARM 11MG/24HR N19983 001 JAN 28, 1992
+ 22MG/24HR N19983 002 JAN 28, 1992
@ 11MG/24HR N19983 001 JAN 28, 1992
@ 22MG/24HR N19983 002 JAN 28, 1992

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITROGLYCERIN
AB1 MYLAN TECHNOLOGIES 0.1MG/HR N75076 001 NOV 12, 1999
AB1 0.2MG/HR N75073 001 NOV 12, 1999
AB1 0.4MG/HR N75075 001 NOV 12, 1999
AB1 0.6MG/HR N74992 001 NOV 12, 1999

INJECTABLE; INJECTION
NITROGLYCERIN
AP SMITH AND NEPHEW 5MG/ML N70633 001 JUN 19, 1986

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN
@ SMITH AND NEPHEW 5MG/ML N70633 001 JUN 19, 1986

OINTMENT; TRANSDERMAL
NITROGLYCERIN
ALTANA 2% N87355 001 JUL 08, 1988
+ 2% N87355 001 JUL 08, 1988

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY
+ POHL BOSKAMP 0.4MG/SPRAY N18705 002 JAN 10, 1997

OLANZAPINE

TABLET; ORAL
ZYPREXA
+ LILLY 2.5MG N20592 001 SEP 30, 1996
2.5MG N20592 001 SEP 30, 1996

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA PHARMS 10MG N19810 003 OCT 05, 1995
ASTRAZENECA 10MG N19810 003 OCT 05, 1995

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ZOFRAN ODT
GLAXO WELLCOME EQ 4MG BASE N20781 001 JAN 27, 1999
+ EQ 8MG BASE N20781 002 JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL
ZOFRAN
+ GLAXO WELLCOME EQ 8MG BASE N20103 002 DEC 31, 1992
EQ 8MG BASE N20103 002 DEC 31, 1992
+ EQ 24MG BASE N20103 003 AUG 27, 1999

ORLISTAT

CAPSULE; ORAL
XENICAL
+ ROCHE 120MG N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
AB KIEL 100MG N40249 001 JAN 29, 1999

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL
TAMIFLU
+ ROCHE EQ 75MG BASE N21087 001 OCT 27, 1999

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MIKART 5MG/5ML N75039 001 JAN 29, 1999

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
+ ALZA 15MG N20897 003 JUN 22, 1999

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
+ PFIZER
@

EQ 125MG BASE/5ML — N60595 001
EQ 125MG BASE/5ML — N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
+ PFIZER
+
@
@

EQ 250MG BASE/VIAL — N60586 001
EQ 500MG BASE/VIAL — N60586 002
EQ 250MG BASE/VIAL — N60586 001
EQ 500MG BASE/VIAL — N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
+ PFIZER
@

EQ 5MG BASE/GM; 10,000 UNITS/GM — N61841 001
EQ 5MG BASE/GM; 10,000 UNITS/GM — N61841 001

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN
+ PFIZER
@

EQ 100MG BASE; 100,000 UNITS — N61009 001
EQ 100MG BASE; 100,000 UNITS — N61009 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AA + PARKEDALE
AA
AA +
@

EQ 250MG BASE — **N60521 001**
EQ 250MG BASE — **N62310 001**
EQ 250MG BASE — N62310 001
EQ 250MG BASE — N60521 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL
SMITHKLINE BEECHAM

EQ 10MG BASE — N20885 001 OCT 09, 1998
EQ 20MG BASE — N20885 002 OCT 09, 1998
EQ 30MG BASE — N20885 003 OCT 09, 1998
+ EQ 40MG BASE — N20885 004 OCT 09, 1998
@ EQ 10MG BASE — N20885 001 OCT 09, 1998
@ EQ 20MG BASE — N20885 002 OCT 09, 1998
@ EQ 30MG BASE — N20885 003 OCT 09, 1998
@ EQ 40MG BASE — N20885 004 OCT 09, 1998

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
+ SMITHKLINE BEECHAM
+

EQ 12.5MG BASE — N20936 001 FEB 16, 1999
EQ 25MG BASE — N20936 002 FEB 16, 1999

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC
ALAMAST
+ SANTEN

0.1% — N21079 001 SEP 24, 1999

PEMOLINE

TABLET; ORAL
CYLERT
AB ABBOTT
AB +
+
+

37.5MG — N16832 002
75MG — N16832 003
18.75MG — N16832 001
37.5MG — N16832 002
75MG — N16832 003
18.75MG — N16832 001

PEMOLINE
AB COPLEY PHARM

37.5MG — N75030 001 JAN 29, 1999

PEMOLINE

TABLET; ORAL

	PEMOLINE			
AB	COPLEY PHARM	**75MG**	**N75030 002**	JAN 29, 1999
AB	INVAMED	**37.5MG**	**N75286 002**	JUN 30, 1999
AB		**75MG**	**N75286 003**	JUN 30, 1999

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	TALWIN 50		
@	SANOFI SYNTHELABO	EQ 50MG BASE	N16732 001
@	STERLING WINTHROP	EQ 50MG BASE	N16732 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	IMPAX PHARM	**400MG**	**N75093 001**	AUG 10, 1999
AB	SIDMAK LABS NJ	**400MG**	**N74874 001**	MAY 25, 1999
AB	TEVA	**400MG**	**N75199 001**	SEP 03, 1999
AB	TORPHARM	**400MG**	**N75191 001**	JUN 09, 1999
	PENTOXIL			
AB	UPSHER SMITH	**400MG**	**N74962 001**	MAR 31, 1999

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON			
@	HUESCHEN	2MG	N20184 001	DEC 30, 1993
@		4MG	N20184 002	DEC 30, 1993
@		8MG	N20184 003	DEC 30, 1993
@	SOLVAY	2MG	N20184 001	DEC 30, 1993

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON			
@	SOLVAY	4MG	N20184 002	DEC 30, 1993
@		8MG	N20184 003	DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

	PHENAZINE			
AA	MAST MM	**35MG**	**N86523 001**	
AA		**35MG**	**N86524 001**	
AA		**35MG**	**N86525 001**	
@		35MG	N86523 001	
@		35MG	N86524 001	
@		35MG	N86525 001	

TABLET; ORAL

	PHENAZINE			
AA	MAST MM	**35MG**	**N87305 001**	
@		35MG	N87305 001	
	PHENDIMETRAZINE TARTRATE			
AA	MFG CHEMISTS	**35MG**	**N85914 001**	
@		35MG	N85914 001	
AA	PVT FORM	**35MG**	**N85697 001**	
@		35MG	N85697 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	FASTIN			
AA	+ SMITHKLINE BEECHAM	**30MG**	**N17352 001**	
@		30MG	N17352 001	
	PHENTERMINE HCL			
AA	EON	**30MG**	**N86945 001**	JUL 20, 1983
AA	+	**30MG**	**N86945 001**	JUL 20, 1983

PHENYTOIN SODIUM

INJECTABLE; INJECTION

	PHENYTOIN SODIUM		
AP	STERIS	**50MG/ML**	**N85434 001**

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
@ STERIS — 50MG/ML — N85434 001

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOS
TAKEDA — EQ 15MG BASE — N21073 001 JUL 15, 1999
EQ 30MG BASE — N21073 002 JUL 15, 1999
\+ EQ 45MG BASE — N21073 003 JUL 15, 1999

POLYETHYLENE GLYCOL 3350

POWDER FOR RECONSTITUTION; ORAL
MIRALAX
\+ BRAINTREE — 17GM/SCOOPFUL — N20698 001 FEB 18, 1999

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
AT ALCON — **10,000 UNITS/ML; EQ 1MG BASE/ML** — **N64211 001** APR 13, 1998
AT FALCON PHARMS — **10,000 UNITS/ML; EQ 1MG BASE/ML** — **N64211 001** APR 13, 1998

> ADD > PORACTANT ALPHA

> ADD > SUSPENSION; INTRATRACHEAL
> ADD > CUROSURF
> ADD > \+ DEY — 80MG/ML — N20744 001 NOV 18, 1999
> ADD >

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K
AB KV PHARM — **8MEQ** — **N18238 001**
AB ROBINS AH — **8MEQ** — **N18238 001**
MICRO-K 10
AB \+ KV PHARM — **10MEQ** — **N18238 002** MAY 14, 1984
AB \+ ROBINS AH — **10MEQ** — **N18238 002** MAY 14, 1984

GRANULE, FOR RECONSTITUTION ER; ORAL
MICRO-K LS
@ KV PHARM — 20MEQ/PACKET — N19561 003 AUG 26, 1988
@ ROBINS AH — 20MEQ/PACKET — N19561 003 AUG 26, 1988

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
AP AM PHARM PARTNERS — **3MEQ/ML** — **N80225 003**
\+ 3MEQ/ML — N80225 003
\+ MILES — **4MEQ/ML** — **N80195 004**
@ 4MEQ/ML — N80195 004
AP STERIS — **2MEQ/ML** — **N86208 001**
AP **2MEQ/ML** — **N89163 001** MAR 10, 1988
AP **2MEQ/ML** — **N89421 001** JAN 02, 1987
AP \+ **3MEQ/ML** — **N86210 001**
@ 2MEQ/ML — N86208 001
@ 2MEQ/ML — N89163 001 MAR 10, 1988
@ 2MEQ/ML — N89421 001 JAN 02, 1987
@ 3MEQ/ML — N86210 001

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION
THAM-E
\+ ABBOTT — 370MG/VIAL;1.75GM/VIAL; 36GM/VIAL — N13025 001
@ 370MG/VIAL;1.75GM/VIAL; 36GM/VIAL — N13025 001

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
POTASSIUM CITRATE

	@	MISSION PHARMA	10MEQ/PACKET	N19647 002 OCT 13, 1988
	@		20MEQ/PACKET	N19647 001 OCT 13, 1988
	@	UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988
	@		20MEQ/PACKET	N19647 001 OCT 13, 1988

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC
BETADINE

	+	ALCON	5%	N18634 001 DEC 17, 1986
	+	PURDUE FREDERICK	5%	N18634 001 DEC 17, 1986

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HCL

AB		ZENITH GOLDLINE	EQ 2MG BASE	N71995 001 MAY 16, 1989
AB			EQ 2MG BASE	N71995 001 SEP 12, 1988
AB			EQ 5MG BASE	N71745 001 MAY 16, 1989
AB			EQ 5MG BASE	N71745 001 SEP 12, 1988

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA		HALSEY	15MG/5ML	N40287 001 MAY 28, 1999
AA		UDL	15MG/5ML	N40323 001 MAY 13, 1999

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	+	STERIS	40MG/ML	N83767 001
	@		40MG/ML	N83767 001

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

AB		ALCON	1%	N17469 001
AB		FALCON PHARMS	1%	N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL

	+	MERCK	EQ 20MG PHOSPHATE/ML	N11583 002
	@		EQ 20MG PHOSPHATE/ML	N11583 002

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA

BP	+	MERCK	20MG/ML	N10562 001
	+		20MG/ML	N10562 001
		PREDNISOLONE TEBUTATE		
BP		STERIS	20MG/ML	N83362 001 FEB 17, 1984
	@		20MG/ML	N83362 001 FEB 17, 1984

PREDNISONE

TABLET; ORAL
ORASONE

AB		SOLVAY	50MG	N85999 001
	@		50MG	N85999 001
		PREDNISONE		
BX		PHARMAVITE	5MG	N84662 002
	@		5MG	N84662 002

PROBENECID

TABLET; ORAL
BENEMID

AB	+	MERCK	500MG	N07898 004

PROBENECID

TABLET; ORAL

	BENEMID		
	@ MERCK	500MG	N07898 004
	PROBENECID		
AB	MYLAN	500MG	N84211 002
AB	+	500MG	N84211 002

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROCAINAMIDE HCL		
AP	SMITH AND NEPHEW	100MG/ML	N88530 001 MAR 04, 1985
AP		500MG/ML	N88531 001 MAR 04, 1985
	@	100MG/ML	N88530 001 MAR 04, 1985
	@	500MG/ML	N88531 001 MAR 04, 1985
AP	STERIS	100MG/ML	N87079 001
AP		500MG/ML	N87080 001
	@	100MG/ML	N87079 001
	@	500MG/ML	N87080 001

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

	PROCHLORPERAZINE EDISYLATE		
AP	SMITH AND NEPHEW	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986
	@	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986
AP	STERIS	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987
	@	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

	COMPAZINE		
	SMITHKLINE BEECHAM	EQ 10MG BASE	N21019 001 OCT 06, 1999

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

	COMPAZINE		
	SMITHKLINE BEECHAM	EQ 15MG BASE	N21019 002 OCT 06, 1999

PROGESTERONE

CAPSULE; ORAL

	PROMETRIUM		
+	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998
		100MG	N19781 001 MAY 14, 1998
		200MG	N19781 002 OCT 15, 1999
+		300MG	N19781 003 OCT 15, 1999

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROMAZINE HCL		
AP	STERIS	50MG/ML	N84517 001
		25MG/ML	N84510 001
	@	25MG/ML	N84510 001
	@	50MG/ML	N84517 001
	SPARINE		
AP	+ WYETH AYERST	50MG/ML	N10349 006
	+	50MG/ML	N10349 006

PROPOFOL

INJECTABLE; INJECTION

	DIPRIVAN		
AB	+ ZENECA	10MG/ML	N19627 002 JUN 11, 1996
	+	10MG/ML	N19627 002 JUN 11, 1996
	PROPOFOL		
AB	GENSIA SICOR PHARMS	10MG/ML	N75102 001 JAN 04, 1999

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		INDERAL LA		
AB	+	WYETH AYERST	60MG	N18553 004 MAR 18, 1987
AB	+		80MG	N18553 002 APR 19, 1983
AB	+		120MG	N18553 003 APR 19, 1983
AB	+		160MG	N18553 001 APR 19, 1983
	+		60MG	N18553 004 MAR 18, 1987
	+		80MG	N18553 002 APR 19, 1983
	+		120MG	N18553 003 APR 19, 1983
	+		160MG	N18553 001 APR 19, 1983
		PROPRANOLOL HCL		
AB		INWOOD LABS	60MG	N72499 001 APR 11, 1989
AB			80MG	N72500 001 APR 11, 1989
AB			120MG	N72501 001 APR 11, 1989
AB			160MG	N72502 001 APR 11, 1989
	@		60MG	N72499 001 APR 11, 1989
	@		80MG	N72500 001 APR 11, 1989
	@		120MG	N72501 001 APR 11, 1989
	@		160MG	N72502 001 APR 11, 1989

INJECTABLE; INJECTION

		INDERAL		
AP	+	WYETH AYERST	1MG/ML	N16419 001
	+		1MG/ML	N16419 001
		PROPRANOLOL HCL		
AP		SMITH AND NEPHEW	1MG/ML	N70137 001 APR 15, 1986
	@		1MG/ML	N70137 001 APR 15, 1986

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

		ACIPHEX		
	+	EISAI	20MG	N20973 002 AUG 19, 1999

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

		TRITEC		
	+	GLAXO WELLCOME	400MG	N20559 001 AUG 08, 1996
	@		400MG	N20559 001 AUG 08, 1996

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

		RANITIDINE HCL		
AB		GRANUTEC PHARMS	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB			EQ 300MG BASE	N74488 002 JUL 31, 1997
AB		NOVOPHARM NC	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB			EQ 300MG BASE	N74488 002 JUL 31, 1997
AB		PAR PHARM	EQ 150MG BASE	N75180 001 JAN 28, 1999
AB			EQ 300MG BASE	N75180 002 JAN 28, 1999

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

		RAPLON		
		ORGANON	100MG/VIAL	N20984 001 AUG 18, 1999
	+		200MG/VIAL	N20984 002 AUG 18, 1999

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ULTIVA

>ADD>		ABBOTT	EQ 1MG BASE/VIAL	N20630 001 JUL 12, 1996
>ADD>			EQ 2MG BASE/VIAL	N20630 002 JUL 12, 1996
>ADD>	+		EQ 5MG BASE/VIAL	N20630 003 JUL 12, 1996
>DLT>		GLAXO WELLCOME	EQ 1MG BASE/VIAL	N20630 001 JUL 12, 1996
>DLT>			EQ 2MG BASE/VIAL	N20630 002 JUL 12, 1996
>DLT>	+		EQ 5MG BASE/VIAL	N20630 003 JUL 12, 1996

RIFAMPIN

INJECTABLE; INJECTION
RIFADIN

AP	+	HOECHST MARION RSSL	**600MG/VIAL**	**N50627 001 MAY 25, 1989**
	+		600MG/VIAL	N50627 001 MAY 25, 1989

RIFAMPIN

AP		BEDFORD	**600MG/VIAL**	**N64217 001 OCT 29, 1999**

RISPERIDONE

TABLET; ORAL
RISPERDAL

	JANSSEN	0.25MG	N20272 008 MAY 10, 1999
+		0.5MG	N20272 007 JAN 27, 1999

RITONAVIR

CAPSULE; ORAL
NORVIR

	ABBOTT	100MG	N20945 001 JUN 29, 1999

RITONAVIR

SOLUTION; ORAL
NORVIR

	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996
+		80MG/ML	N20659 001 MAR 01, 1996

ROFECOXIB

SUSPENSION; ORAL
VIOXX

	MERCK	12.5MG/5ML	N21052 001 MAY 20, 1999
+		25MG/5ML	N21052 002 MAY 20, 1999

TABLET; ORAL
VIOXX

	MERCK	12.5MG	N21042 001 MAY 20, 1999
+		25MG	N21042 002 MAY 20, 1999

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP

	SMITHKLINE BEECHAM	EQ 3MG BASE	N20658 006 JAN 27, 1999
		EQ 4MG BASE	N20658 007 JAN 27, 1999

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA

	SMITHKLINE BEECHAM	EQ 2MG BASE	N21071 002 MAY 25, 1999
		EQ 4MG BASE	N21071 003 MAY 25, 1999
+		EQ 8MG BASE	N21071 004 MAY 25, 1999

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR 200MG N20828 001 NOV 07, 1997
+ ROCHE 200MG N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR EQ 200MG BASE N20628 001 DEC 06, 1995
+ ROCHE EQ 200MG BASE N20628 001 DEC 06, 1995

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
ELDEPRYL
@ SOMERSET 5MG N19334 001 JUN 05, 1989

SELEGILINE HCL
AB + SOMERSET 5MG N19334 001 JUN 05, 1989

SILVER SULFADIAZINE

CREAM; TOPICAL
THERMAZENE
AB KENDALL LP **1%** **N18810 001 DEC 23, 1985**
AB SHERWOOD MEDCL **1%** **N18810 001 DEC 23, 1985**

SIROLIMUS

SOLUTION; ORAL
RAPAMUNE
+ WYETH AYERST 1MG/ML N21083 001 SEP 15, 1999

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL
+ MEDICIS 3GM/TEASPOONFUL N20573 001 APR 30, 1996
+ UCYCLYD 3GM/TEASPOONFUL N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL
+ MEDICIS 500MG N20572 001 MAY 13, 1996
+ UCYCLYD 500MG N20572 001 MAY 13, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN PRESERVATIVE FREE
+ PHARMACIA AND UPJOHN 1.5MG/VIAL N20280 004 AUG 24, 1995
0.2MG/VIAL N20280 001 JAN 27, 1998
0.4MG/VIAL N20280 002 JAN 27, 1998
0.6MG/VIAL N20280 003 JAN 27, 1998
0.8MG/VIAL N20280 005 JAN 27, 1998
1MG/VIAL N20280 008 JAN 27, 1998
1.2MG/VIAL N20280 009 JAN 27, 1998
1.4MG/VIAL N20280 010 JAN 27, 1998
1.5MG/VIAL N20280 004 AUG 24, 1995
1.6MG/VIAL N20280 011 JAN 27, 1998
1.8MG/VIAL N20280 012 JAN 27, 1998
+ 2MG/VIAL N20280 013 JAN 27, 1998

HUMATROPE
BX LILLY 6MG/VIAL N19640 005 FEB 04, 1999

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION

		HUMATROPE		
	+	LILLY	12MG/VIAL	N19640 006 FEB 04, 1999
	+		24MG/VIAL	N19640 007 FEB 04, 1999

SOYBEAN OIL

INJECTABLE; INJECTION

		INTRALIPID 10%		
AP	+	FRESENIUS KABI	10%	N17643 001
AP	+	PHARMACIA AND UPJOHN	10%	N17643 001
		INTRALIPID 20%		
AP	+	FRESENIUS KABI	20%	N18449 001
AP	+		20%	N20248 001 AUG 07, 1996
AP	+	PHARMACIA AND UPJOHN	20%	N18449 001
AP	+		20%	N20248 001 AUG 07, 1996
		INTRALIPID 30%		
AP	+	FRESENIUS KABI	30%	N19942 001 DEC 30, 1993
AP	+	PHARMACIA AND UPJOHN	30%	N19942 001 DEC 30, 1993

SPIRONOLACTONE

TABLET; ORAL

		ALDACTONE		
AB		SEARLE	50MG	N12151 008 DEC 30, 1982
AB	+		100MG	N12151 010 DEC 30, 1983
			50MG	N12151 008 DEC 30, 1982
	+		100MG	N12151 010 DEC 30, 1983
		SPIRONOLACTONE		
AB		MUTUAL PHARM	50MG	N89424 002 AUG 11, 1999
AB			100MG	N89424 003 AUG 11, 1999
AB		PUREPAC PHARM	25MG	N87998 001 OCT 14, 1983

SPIRONOLACTONE

TABLET; ORAL

		SPIRONOLACTONE		
AB		PUREPAC PHARM	50MG	N40353 001 JUL 29, 1999
AB			100MG	N40353 002 JUL 29, 1999
	@		25MG	N87998 001 OCT 14, 1983

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

		SODIUM SULFACETAMIDE		
AT		AKORN	10%	N83021 001
AT			15%	N83021 002
AT			30%	N83021 003
	@		10%	N83021 001
	@		15%	N83021 002
	@		30%	N83021 003
		SULFACETAMIDE SODIUM		
AT		AKORN	10%	N40215 001 MAY 25, 1999
AT			30%	N40216 001 MAY 25, 1999

SULFADIAZINE

TABLET; ORAL

		SULFADIAZINE		
AB	+	EON	500MG	N40091 001 JUL 29, 1994
	+		500MG	N40091 001 JUL 29, 1994
AB		GLOBAL PHARM	500MG	N80081 001
	@		500MG	N80081 001
AB		LANNETT	500MG	N80084 001
	@		500MG	N80084 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

		SULFAMETHOXAZOLE AND TRIMETHOPRIM		
AP		STERIS	80MG/ML;16MG/ML	N71556 001 DEC 29, 1987

SULFAMETHOXAZOLE; TRIMETHOPRIM

	INJECTABLE; INJECTION			
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
	@ STERIS	80MG/ML;16MG/ML	N71556 001	
			DEC 29, 1987	

TACROLIMUS

	CAPSULE; ORAL			
	PROGRAF			
	+ FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001	
			APR 08, 1994	
		EQ 0.5MG BASE	N50708 003	
			AUG 24, 1998	
		EQ 1MG BASE	N50708 001	
			APR 08, 1994	

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

	INJECTABLE; INJECTION			
	A-N STANNOUS AGGREGATED ALBUMIN			
	@ NORTH AM CHEMS	N/A	N17916 001	
	@ SYNCOR PHARMS	N/A	N17916 001	
	PULMOLITE			
BS	CIS	N/A	N17776 001	
BS	DUPONT PHARMS	N/A	N17776 001	

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

	INJECTABLE; INJECTION			
	MICROLITE			
	CIS	N/A	N18263 001	
			MAR 25, 1983	
	DUPONT PHARMS	N/A	N18263 001	
			MAR 25, 1983	

TECHNETIUM TC-99M DEPREOTIDE

	INJECTABLE; INJECTION			
	NEO TECT KIT			
	+ DIATIDE	N/A	N21012 001	
			AUG 03, 1999	

TECHNETIUM TC-99M DISOFENIN KIT

	INJECTABLE; INJECTION			
	HEPATOLITE			
	CIS	N/A	N18467 001	
			MAR 16, 1982	
	DUPONT PHARMS	N/A	N18467 001	
			MAR 16, 1982	

TECHNETIUM TC-99M LIDOFENIN KIT

	INJECTABLE; INJECTION			
	TECHNESCAN HIDA			
	DRAXIMAGE	N/A	N18489 001	
			OCT 31, 1986	
	@	N/A	N18489 001	
			OCT 31, 1986	

TECHNETIUM TC-99M MEDRONATE KIT

	INJECTABLE; INJECTION			
	OSTEOLITE			
AP	CIS	**N/A**	**N17972 001**	
AP	DUPONT PHARMS	**N/A**	**N17972 001**	

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

	INJECTABLE; INJECTION			
	PYROLITE			
	CIS	N/A	N17684 001	
	DUPONT PHARMS	N/A	N17684 001	

TEMOZOLOMIDE

	CAPSULE; ORAL			
	TEMODAR			
	SCHERING	5MG	N21029 001	
			AUG 11, 1999	
		20MG	N21029 002	
			AUG 11, 1999	
		100MG	N21029 003	
			AUG 11, 1999	
	+	250MG	N21029 004	
			AUG 11, 1999	

TERBUTALINE SULFATE

INJECTABLE; INJECTION

	BRETHINE			
AP	+ NOVARTIS	1MG/ML		N18571 001
	+	1MG/ML		N18571 001
	BRICANYL			
AP	+ HOECHST MARION RSSL	1MG/ML		N17466 001
	@	1MG/ML		N17466 001

TABLET; ORAL

	BRETHINE			
BP	NOVARTIS	2.5MG		N17849 001
BP	+	5MG		N17849 002
	+	2.5MG		N17849 001
		5MG		N17849 002
	BRICANYL			
BP	HOECHST MARION RSSL	2.5MG		N17618 001
BP		5MG		N17618 002
	@	2.5MG		N17618 001
	@	5MG		N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

	PARATHAR			
	+ RHONE POULENC RORER	200 UNITS/VIAL		N19498 001
				DEC 23, 1987
	@	200 UNITS/VIAL		N19498 001
				DEC 23, 1987

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

	TESTOSTERONE ENANTHATE			
	STERIS	100MG/ML		N85599 001
	@	100MG/ML		N85599 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL			
AB	PUREPAC PHARM	250MG		N60290 001
AB		500MG		N60290 002
	@	250MG		N60290 001
	@	500MG		N60290 002

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYN			
AB	PFIPHARMECS	250MG		N60082 003
AB		500MG		N60082 004
	@	250MG		N60082 003
	@	500MG		N60082 004

THEOPHYLLINE

CAPSULE; ORAL

	BRONKODYL			
	@ SANOFI SYNTHELABO	100MG		N85264 001
	@	200MG		N85264 002
	@ STERLING WINTHROP	100MG		N85264 001
	@	200MG		N85264 002

CAPSULE, EXTENDED RELEASE; ORAL

	THEOCLEAR L.A.-130			
BC	+ CENT PHARMS	130MG		N86569 001
				MAY 27, 1982
	@ SCHWARZ PHARMA	130MG		N86569 001
				MAY 27, 1982
	THEOCLEAR L.A.-260			
BC	+ CENT PHARMS	260MG		N86569 002
				MAY 27, 1982
	@ SCHWARZ PHARMA	260MG		N86569 002
				MAY 27, 1982

INJECTABLE; INJECTION

	THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
	@ B BRAUN	40MG/100ML		N19083 001
				NOV 07, 1984
	@ MCGAW	40MG/100ML		N19083 001
				NOV 07, 1984
	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
	@ B BRAUN	80MG/100ML		N19083 002
				NOV 07, 1984
	@ MCGAW	80MG/100ML		N19083 002
				NOV 07, 1984
	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
	@ B BRAUN	160MG/100ML		N19083 003
				NOV 07, 1984
	@ MCGAW	160MG/100ML		N19083 003
				NOV 07, 1984

THEOPHYLLINE

SYRUP; ORAL

	AQUAPHYLLIN		
AA	FERNDALE LABS	**80MG/15ML**	**N87917 001 JAN 18, 1983**
@		80MG/15ML	N87917 001 JAN 18, 1983

TABLET, EXTENDED RELEASE; ORAL

	SUSTAIRE		
BC	ROERIG	100MG	**N85665 001**
BC		300MG	**N85665 002**
@		100MG	N85665 001
@		300MG	N85665 002

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

	THIOTHIXENE HCL		
AA	ALPHARMA	**EQ 5MG BASE/ML**	**N70969 001 OCT 16, 1987**
@		EQ 5MG BASE/ML	N70969 001 OCT 16, 1987

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

	GABITRIL		
+	ABBOTT	2MG	N20646 005 APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID		
	@ ROCHE	125MG	**N19979 001 MAR 24, 1993**
AB +	SYNTEX	**250MG**	**N19979 002 OCT 31, 1991**
@		125MG	N19979 001 MAR 24, 1993
+	SYNTEX USA	250MG	N19979 002 OCT 31, 1991
	TICLOPIDINE HCL		
AB	EON	**250MG**	**N75326 001 AUG 20, 1999**

> ADD >
> ADD >

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLOPIDINE HCL		
AB	GENPHARM	**250MG**	**N75161 001 SEP 13, 1999**
AB	INVAMED	**250MG**	**N75318 001 AUG 20, 1999**
AB	MYLAN	**250MG**	**N75316 001 NOV 02, 1999**
AB	PUREPAC PHARM	**250MG**	**N75253 001 AUG 20, 1999**
AB	TEVA	**250MG**	**N75149 001 AUG 20, 1999**
AB	TORPHARM	**250MG**	**N75089 001 JUL 01, 1999**

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE		
AB	ALCON	**EQ 0.25% BASE**	**N20963 001 OCT 21, 1998**
AB		**EQ 0.5% BASE**	**N20963 002 OCT 21, 1998**
AB	FALCON PHARMS	**EQ 0.25% BASE**	**N20963 001 OCT 21, 1998**
AB		**EQ 0.5% BASE**	**N20963 002 OCT 21, 1998**

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE		
AT	ADV REMEDIES	**EQ 0.5% BASE**	**N74466 001 MAR 25, 1997**
AT	AKORN	**EQ 0.5% BASE**	**N74466 001 MAR 25, 1997**
AT	ALCON	**EQ 0.25% BASE**	**N74261 001 APR 28, 1995**
AT		**EQ 0.5% BASE**	**N74262 001 APR 28, 1995**
@	FALCON PHARMS	EQ 0.25% BASE	N74261 001 APR 28, 1995
@		EQ 0.5% BASE	N74262 001 APR 28, 1995

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBREX

AT	+	ALCON	0.3%	N50541 001
AT	+	FALCON PHARMS	0.3%	N50541 001

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP		APOTHECON	EQ 40MG BASE/ML	N64026 001 MAY 31, 1994
	@		EQ 40MG BASE/ML	N64026 001 MAY 31, 1994

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
HYCAMTIN

	+	SMITHKLINE	EQ 4MG BASE/VIAL	N20671 001 MAY 28, 1996
	+	SMITHKLINE BEECHAM	EQ 4MG BASE/VIAL	N20671 001 MAY 28, 1996

TRETINOIN

GEL; TOPICAL
RETIN-A MICRO

	+	ADV POLYMER	0.1%	N20475 001 FEB 07, 1997
	+	JOHNSON AND JOHNSON	0.1%	N20475 001 FEB 07, 1997

SOLUTION; TOPICAL
TRETINOIN

AT		MORTON GROVE	0.05%	N75260 001 JAN 25, 1999

TRIAMCINOLONE

TABLET; ORAL
ARISTOCORT

BP		FUJISAWA HLTHCARE	4MG	N11161 007
BP	+		8MG	N11161 011

TRIAMCINOLONE

TABLET; ORAL
ARISTOCORT

		FUJISAWA HLTHCARE	1MG	N11161 009
			2MG	N11161 004
BP		LEDERLE	2MG	N11161 004
BP			4MG	N11161 007
BP	+		8MG	N11161 011
			1MG	N11161 009

TRIAMCINOLONE

BP		ROXANE	2MG	N84708 001
BP			4MG	N84709 001
BP			8MG	N84707 001
	@		2MG	N84708 001
	@		4MG	N84709 001
	@		8MG	N84707 001
BP		TEVA	4MG	N84775 001
	@		4MG	N84775 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
ARISTOCORT

AT	FUJISAWA HLTHCARE	0.025%	N83017 003
AT		0.1%	N83016 004
AT		0.5%	N83015 002
AT	LEDERLE	0.025%	N83017 003
AT		0.1%	N83016 004
AT		0.5%	N83015 002

ARISTOCORT A

AT	FUJISAWA HLTHCARE	0.025%	N83017 004
AT		0.025%	N88818 001 OCT 16, 1984
AT		0.1%	N83016 005
AT		0.1%	N88819 001 OCT 16, 1984
AT		0.5%	N83015 003
AT		0.5%	N88820 001 OCT 16, 1984
AT	LEDERLE	0.025%	N83017 004
AT		0.025%	N88818 001 OCT 16, 1984
AT		0.1%	N83016 005
AT		0.1%	N88819 001 OCT 16, 1984
AT		0.5%	N83015 003

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
ARISTOCORT A
AT LEDERLE 0.5% N88820 001 OCT 16, 1984

GEL; TOPICAL
ARISTOGEL
@ FUJISAWA HLTHCARE 0.1% N83380 001
@ LEDERLE 0.1% N83380 001

LOTION; TOPICAL
KENALOG
@ APOTHECON 0.025% N11602 003
@ 0.1% N11602 001
@ BRISTOL MYERS SQUIBB 0.025% N11602 003
@ 0.1% N11602 001

OINTMENT; TOPICAL
ARISTOCORT
AT FUJISAWA HLTHCARE 0.1% N80750 004
AT 0.5% N80745 002
AT LEDERLE 0.1% N80750 004
AT 0.5% N80745 002

ARISTOCORT A
AT FUJISAWA HLTHCARE 0.1% N80750 003
AT 0.1% N88780 001
OCT 01, 1984
AT + 0.5% N80745 003
@ 0.5% N88781 001
OCT 05, 1984
AT LEDERLE 0.1% N80750 003
AT 0.1% N88780 001
OCT 01, 1984
AT + 0.5% N80745 003
@ 0.5% N88781 001
OCT 05, 1984

TRIAMCINOLONE ACETONIDE
AT ALPHARMA 0.5% N89913 001
DEC 23, 1988
@ 0.5% N89913 001
DEC 23, 1988

TRIAMCINOLONE DIACETATE

SYRUP; ORAL
ARISTOCORT
FUJISAWA HLTHCARE 2MG/5ML N11960 004

TRIAMCINOLONE DIACETATE

SYRUP; ORAL
ARISTOCORT
LEDERLE 2MG/5ML N11960 004

TRIAMTERENE

CAPSULE; ORAL
DYRENIUM
>DLT< SMITHKLINE BEECHAM 50MG N13174 001
>DLT< + 100MG N13174 002
>ADD< WELLSPRING PHARM 50MG N13174 001
>ADD< + 100MG N13174 002

TRICHLORMETHIAZIDE

TABLET; ORAL
TRICHLORMAS
BP MAST MM 4MG N86259 001
@ 4MG N86259 001

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
TRIFLURIDINE
>ADD< AT ALCON 1% N74311 001
OCT 06, 1995
>ADD< AT STERIS 1% N74311 001
>DLT< OCT 06, 1995
>DLT<

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL
TRIHEXYPHENIDYL HCL
AA MIKART 2MG/5ML N40251 001
SEP 27, 1999

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TIGAN
>ADD< AP + KING PHARMS 100MG/ML N17530 001
>DLT< AP + ROBERTS LABS 100MG/ML N17530 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL

AP	SMITH AND NEPHEW	**100MG/ML**	**N88960 001**	**APR 04, 1986**
	@	100MG/ML	N88960 001	APR 04, 1986

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL
SULFA-TRIPLE #2

AB	+ GLOBAL PHARM	**167MG;167MG;167MG**	**N80079 001**	
	@	167MG;167MG;167MG	N80079 001	

TRIPLE SULFOID

AB	PAL PAK	**167MG;167MG;167MG**	**N80094 001**	
	+	167MG;167MG;167MG	N80094 001	

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AT	STERIS	**0.5%**	**N89171 001**	**DEC 28, 1990**
	@	0.5%	N89171 001	DEC 28, 1990

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL
PYLORI-CHEK BREATH TEST

	+ ALIMENTERICS	100MG/VIAL	N20900 001	FEB 04, 1999

VALRUBICIN

SOLUTION;
VALSTAR PRESERVATIVE FREE

	+ ANTHRA	40MG/ML	N20892 001	SEP 25, 1998

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE

	+ ANTHRA	40MG/ML	N20892 001	SEP 25, 1998

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	ABBOTT	**10MG/VIAL**	**N75164 001**	OCT 21, 1999
AP		**20MG/VIAL**	**N75164 002**	OCT 21, 1999
AP	ESI LEDERLE	**10MG/VIAL**	**N75218 001**	AUG 23, 1999
AP		**20MG/VIAL**	**N75218 002**	AUG 23, 1999
AP	GENSIA	**10MG/VIAL**	**N74688 001**	AUG 25, 1999
AP		**20MG/VIAL**	**N74688 002**	AUG 25, 1999

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERAPAMIL HCL

AB	MYLAN	**120MG**	**N75138 001**	APR 20, 1999
AB		**180MG**	**N75138 002**	APR 20, 1999
AB		**240MG**	**N75138 003**	APR 20, 1999

VERELAN

	+ ELAN	120MG	N19614 001	MAY 29, 1990
	+	180MG	N19614 003	JAN 09, 1992
	+	240MG	N19614 002	MAY 29, 1990
AB	+ ELAN PHARM	**120MG**	**N19614 001**	MAY 29, 1990
AB	+	**180MG**	**N19614 003**	JAN 09, 1992
AB	+	**240MG**	**N19614 002**	MAY 29, 1990

INJECTABLE; INJECTION
VERAPAMIL HCL

AP	SMITH AND NEPHEW	**2.5MG/ML**	**N70696 001**	**JUL 31, 1987**
	@	2.5MG/ML	N70696 001	JUL 31, 1987

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	DURAMED	**120MG**	**N75072 001**	
			MAY 25, 1999	
AB		**240MG**	**N75072 003**	
			MAY 25, 1999	

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCRISTINE SULFATE PFS			
AP	GENSIA SICOR PHARMS	**1MG/ML**	**N75493 001**	
			SEP 01, 1999	

VITAMIN A PALMITATE

CAPSULE; ORAL

	DEL-VI-A			
AA	DBL RAY LABS	**EQ 50,000 UNITS BASE**	**N80830 001**	
	@	EQ 50,000 UNITS BASE	N80830 001	

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN			
AB	+ DUPONT MERCK	**2MG**	**N09218 013**	
AB		2MG	N09218 013	
AB		**2.5MG**	**N09218 018**	
AB	+	2.5MG	N09218 018	
AB		**5MG**	**N09218 007**	
AB	+	5MG	N09218 007	
	WARFARIN SODIUM			
AB	TARO	**1MG**	**N40301 002**	
			JUL 15, 1999	
AB		**2MG**	**N40301 003**	
			JUL 15, 1999	
AB		**2.5MG**	**N40301 004**	
			JUL 15, 1999	
AB		**3MG**	**N40301 005**	
			JUL 15, 1999	
AB		**4MG**	**N40301 006**	
			JUL 15, 1999	
AB		**5MG**	**N40301 007**	
			JUL 15, 1999	

WARFARIN SODIUM

TABLET; ORAL

	WARFARIN SODIUM			
AB	TARO	**6MG**	**N40301 008**	
			JUL 15, 1999	
AB		**7.5MG**	**N40301 009**	
			JUL 15, 1999	
AB		**10MG**	**N40301 001**	
			JUL 15, 1999	

XYLOSE

POWDER; ORAL

	XYLO-PFAN			
AA	+ SAVAGE LABS	**25GM/BOT**	**N17605 001**	
	@	25GM/BOT	N17605 001	
	XYLOSE			
AA	LYNE	**25GM/BOT**	**N18856 001**	
			MAR 26, 1987	
	+	25GM/BOT	N18856 001	
			MAR 26, 1987	

ZALEPLON

CAPSULE; ORAL

	SONATA			
	WYETH AYERST	5MG	N20859 001	
			AUG 13, 1999	
	+	10MG	N20859 002	
			AUG 13, 1999	

ZANAMIVIR

CAPSULE; INHALATION

	RELENZA			
	+ GLAXO WELLCOME	5MG	N21036 001	
			JUL 26, 1999	

ACETAMINOPHEN

SUPPOSITORY; RECTAL

	ACEPHEN		
+	G AND W LABS	120MG	N18060 001
+		325MG	N18060 003
			DEC 18, 1986
+		650MG	N18060 002
		120MG	N18060 001
		325MG	N18060 003
			DEC 18, 1986
		650MG	N18060 002
	ACETAMINOPHEN		
	ASCENT PEDS	120MG	N18337 003
			SEP 12, 1983
		325MG	N18337 002
+		650MG	N18337 001
	UPSHER SMITH	120MG	N18337 003
			SEP 12, 1983
		325MG	N18337 002
		650MG	N18337 001
	INFANTS' FEVERALL		
	ASCENT PEDS	80MG	N18337 004
			AUG 26, 1992
	UPSHER SMITH	80MG	N18337 004
			AUG 26, 1992

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CONTAC		
+	SMITHKLINE	8MG;75MG	N18099 001
@		8MG;75MG	N18099 001
	PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE		
	CENT PHARMS	8MG;75MG	N18809 001
			MAY 07, 1984
+		8MG;75MG	N18809 001
			MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

	CONTAC		
	NOVARTIS	12MG;75MG	N19613 001
			JUN 13, 1986
+		12MG;75MG	N19613 001
			JUN 13, 1986
	TRIAMINIC-12		
+	NOVARTIS	12MG;75MG	N18115 001
@		12MG;75MG	N18115 001

CIMETIDINE

SUSPENSION; ORAL

	TAGAMET HB 200		
+	SMITHKLINE BEECHAM	200MG/20ML	N20951 001
			JUL 09, 1999

TABLET; ORAL

	CIMETIDINE		
	DANBURY PHARMA	200MG	N75425 001
			JUL 29, 1999
	ZENITH GOLDLINE	200MG	N75345 001
			JUN 16, 1999

CLOTRIMAZOLE

CREAM; TOPICAL

	LOTRIMIN AF		
	SCHERING PLOUGH	1%	N17619 002
			OCT 27, 1989

LOTION; TOPICAL

	LOTRIMIN AF		
	SCHERING	1%	N18813 002
			OCT 27, 1989

SOLUTION; TOPICAL

	LOTRIMIN AF		
	SCHERING PLOUGH	1%	N17613 002
			OCT 27, 1989

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

	MEDIHALER-EPI		
+	3M	0.3MG/INH	N10374 003
@		0.3MG/INH	N10374 003

FAMOTIDINE

TABLET; ORAL

	PEPCID AC		
	MERCK	10MG	N20902 001
			AUG 05, 1999

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

ALPHARMA	100MG/5ML	N74916 001 APR 30, 1999

TABLET; ORAL
IBUPROFEN

LNK	200MG	N75010 001 MAR 01, 1999
	200MG	N75139 001 MAR 01, 1999
NORTON HN	200MG	N71144 001 JAN 20, 1987
	200MG	N72901 001 DEC 19, 1991
	200MG	N72903 001 DEC 19, 1991
ZENITH GOLDLINE	200MG	N71144 001 JAN 20, 1987
	200MG	N72901 001 DEC 19, 1991
	200MG	N72903 001 DEC 19, 1991

JUNIOR STRENGTH IBUPROFEN

PERRIGO	100MG	N75367 001 APR 22, 1999

IBUPROFEN POTASSIUM

CAPSULE; ORAL
PROVEL

+ NOVARTIS	200MG	N20402 001 APR 20, 1995
+ WHITEHALL ROBINS	200MG	N20402 001 APR 20, 1995

> ADD >

INSULIN ZINC SUSP PURIFIED BEEF

> ADD >

INJECTABLE; INJECTION
LENTE ILETIN II

> ADD >

+ LILLY	100 UNITS/ML	N18477 001
@	100 UNITS/ML	N18477 001

> ADD >

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK

ALPHARMA US PHARM	2%,200MG	N74926 001 APR 16, 1999

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO	2%,200MG	N75329 001 APR 20, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

ALPHARMA US PHARM	100MG	N73507 001 NOV 19, 1993
NMC	100MG	N73507 001 NOV 19, 1993

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

PERRIGO	2%	N75357 001 JUL 30, 1999

MINOXIDIL (FOR WOMEN)

PERRIGO	2%	N75357 002 JUL 30, 1999

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

GRANUTEC	EQ 200MG BASE	N74635 001 JAN 13, 1997
NOVOPHARM NC	EQ 200MG BASE	N74635 001 JAN 13, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALEVE COLD AND SINUS

+ BAYER	EQ 200MG BASE;120MG	N21076 001 NOV 29, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL		
PROSTEP		
+ ELAN PHARM	11MG/24HR	N19983 003 DEC 23, 1998
+	22MG/24HR	N19983 004 DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL		
NICOTINE POLACRILEX		
WATSON LAB	EQ 2MG BASE	N74507 001 MAR 15, 1999
	EQ 4MG BASE	N74707 001 MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL		
TODAY		
@ ALLENDALE PHARMS	1GM	N18683 001 APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001 APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		
PSEUDOEPHEDRINE HCL		
PERRIGO	120MG	N75153 001 FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL		
RANITIDINE HCL		
NOVOPHARM	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001
ZANTAC 75		
+ GLAXO WELLCOME	EQ 75MG BASE	N20520 001 DEC 19, 1995

RANITIDINE HYDROCHLORIDE

TABLET; ORAL		
ZANTAC 75		
+ WARNER LAMBERT	EQ 75MG BASE	N20520 001 DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL		
LAMISIL		
+ NOVARTIS	1%	N20980 001 MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 11 NOV '99

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
506U78 TN=	Treatment of chronic lymphocytic leukemia.	Glaxo Wellcome, Inc. Five Moore Dr. P.O. Box 13398 Durham, NC 27709 DD=09/02/1999
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=04/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/06/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
6-hydroxymethylacylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/27/1999
AP1903 TN=	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Ariad Gene Therapeutics, Inc. 26 Landsdowne St. Cambridge, MA 02139 DD=11/24/1999
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999
Alpha1-proteinase inhibitor (human) TN=	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Centeon LLC 1020 First Ave. King of Prussia, PA 19406 DD=11/24/1999
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Amifostine TN= Ethyol	Treatment of myelodysplastic syndromes.	US Bioscience, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken, PA 19428 DD=10/04/1999
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strasse 76 35041 Marburg Germany DD=10/16/1992 MA=04/01/1999
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia Geneva 27, Switzerland DD=07/19/1999
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999
Azathioprine TN= Imuran	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor New York, NY 10019 DD=09/14/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999
Bexarotene TN= Targretin	Treatment of cutaneous T-cell lymphoma.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999
Botulinum toxin type A TN= Dysport	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited 1 Bath Rd., Maidenhead Berkshire SL6 4UH England, UK DD=10/20/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Caffeine TN= Cafcit	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence, KS 66047 DD=09/20/1988 MA=09/21/1999
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999
Epirubicin TN= Ellence	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo, MI 49001 DD=09/14/1999 MA=09/15/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Etanercept TN= Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998 MA=05/27/1999
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Immunex Corporation 51 University Street Seattle, WA 98101 DD=04/06/1999
Exemestane TN= Aromasin	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn 7000 Portage Road Mail Stop: 0636-298-113 Kalamazoo, MI 49001 DD=09/19/1991 MA=10/21/1999
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Gemtuzumab zogamicin TN=	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories PO Box 8299 Philadelphia, PA 19101 DD=11/24/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Guanfacine TN= Tenex	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona, CA 91718 DD=08/05/1999
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex TN= Allovectin-7	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego, CA 92121 DD=09/30/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=02/12/1999
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea, DD=05/19/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999
L-glutamyl-L-tryptophan TN=	Treatment of AIDS-related Kaposi's sarcoma.	Cytran Incorporated 10230 N.E. Points Dr. Suite 530 Kirkland, WA 98033 DD=10/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999
Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II) TN=	Treatment of malignant mesothelioma.	Aronex Pharmaceuticals, Inc. 8707 Technolgoy Forest Place The Woodlands, TX 77381 DD=09/01/1999
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999
Mitoxantrone TN= Novantrone	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Mitoxantrone TN= Novantrone	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, UK DD=03/22/1999
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Peginterferon alfa-2a TN= PEGASYS	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=09/30/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999
Pentostatin TN= Nipent	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon, CA 94583 DD=11/24/1999
Polyethylene glycol-modified uricase TN= Zurase	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=09/14/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999
Recombinant human insulin-like growth factor-I/insulin -like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999
Silver sulfadiazine and cerium nitrate TN= Flammacerium	Prevention of mortality in severely burned patients.	Synthes (USA) 1690 Russell Road PO Box 1766 Paoli, PA 19301 DD=11/17/1999
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1 DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Somatropin (rDNA origin) TN= Neutropin Depot	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=10/28/1999
Somatropin [rDNA] TN= Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo, MI 49001 DD=07/06/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Temoporfin TN= Foscan	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Scotia Pharmaceuticals Ltd. Scotia House, Castle Business Park Stirling Scotland FK9 4TZ DD=10/28/1999
Temozolomide TN= Temodar	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998 MA=08/11/1999
Teriparatide TN= Parathar	Treatment of idiopathic osteoporosis.	Henri Beaufour Institute USA, Inc. 27 Maple St. Milford, MA 01757 DD=10/28/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K. DD=05/19/1999

Orphan Product Designations and Approvals List
November 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody TN= Cea-Cide	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=08/03/1999
pVGI.1(VEGF2) TN=	Treatment of thromboangiitis obliterans.	Vascular Genetics, Inc. 200 Westpark Corporate Center 4364 South Alston Ave. Durham, NC 27713 DD=11/09/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1999 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NP* NEW PRODUCT (MINT FLAVORED)

REFERENCES

NEW DOSING SCHEDULE

D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS

NEW INDICATION

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION

PATENT USE CODE

U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482 004	ACARBOSE;PRECOSE				I-252	SEP 29, 2001
						I-253	SEP 29, 2001
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAR 31, 2010	U-275		
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAY 31, 2010	U-275		
	020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA				I-262	JUN 02, 2002
	019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
	020560 001	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
	020560 002	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
	020560 003	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
	020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
						NCE	FEB 02, 2004
	020221 001	AMIFOSTINE;ETHYOL				ODE	JUN 24, 2006
>ADD>	020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN KERASTICK	5079262	JUL 28, 2009	U-289	NCE	DEC 03, 2004
>ADD>			5211938	MAY 18, 2010	U-289		
>ADD>			5422093	JUL 28, 2009	U-289		
	020364 002	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
	020364 003	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
	020364 004	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
	020508 001	AMMONIUM LACTATE;LAC-HYDRIN				PED	FEB 29, 2000
	021007 001	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021007 002	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
>ADD>	020884 001	ASPIRIN;AGGRENOX				NC	NOV 22, 2002
	020702 001	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
	020702 002	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
	020702 003	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
	020500 001	ATOVAQUONE;MEPRON				ODE	JAN 05, 2006
						I-255	JAN 05, 2002
	020746 001	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
	020746 002	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
						NE	SEP 21, 2002
	020793 001	CAFFEINE CITRATE;CAFCIT					
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	JUN 02, 2015			
	020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020712 001	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020712 002	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NS	MAY 24, 2002
			5177080	NOV 26, 2011			
	020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
	020863 001	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	020863 002	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
			5286754	FEB 15, 2011			
	020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	5648093	JUL 15, 2014			
	020463 001	CROMOLYN SODIUM;NASALCROM				PED	JUL 03, 2000
	021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
						NP	APR 01, 2002
	020287 001	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 003	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 003	DESMOPRESSIN ACETATE;DDAVP (NEEDS NO REFRIGERATION)	5763407	JUN 29, 2013			
>ADD>	021038 001	DEXMEDETOMIDINE;PRECEDEX				NCE	DEC 17, 2004
	074752 001	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	074752 003	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	074752 004	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010			
			5438072	NOV 22, 2013			
			5698582	JUL 03, 2012			
			5714512	JUL 03, 2012			
	020931 001	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020931 002	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020931 003	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008			
			4619939	OCT 28, 2003			
	020862 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
			5707980	FEB 11, 2117	U-278		
	050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
	020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
						NCE	OCT 19, 2004
	020796 001	ENTACAPONE;COMTAN				ODE	SEP 15, 2006
	050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				I-254	MAR 05, 2002
	020375 001	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 002	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
	020375 004	ESTRADIOL;CLIMARA				NP	MAR 26, 2002
	020908 001	ESTRADIOL;VAGIFEM				NP	MAR 24, 2002
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN					
	010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
	010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
	004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
	020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5210081	FEB 26, 2012			
	020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN 14/14)	RE36247	MAY 02, 2006	U-284		
			RE36247	MAY 02, 2006			
	020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5210081	FEB 26, 2012			
			4826831	MAY 02, 2006			
	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
			RE36247	MAY 02, 2006			
			5210081	FEB 26, 2012			
			5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	021065 003	ETHINYL ESTRADIOL;FEMHRT	4966768	OCT 30, 2007		PED	APR 25, 2000
>ADD>	020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2007		NDF	OCT 25, 1999
>ADD>			4966768	OCT 30, 2007		PED	APR 25, 2000
>ADD>	020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2007	PED	NDF	OCT 25, 1999
>ADD>			4966768	OCT 30, 2007		NDF	OCT 25, 1999
>ADD>	020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2007	PED	PED	APR 25, 2000
>ADD>			4808616	JUL 07, 2006		NCE	OCT 21, 2004
	020753 001	EXEMESTANE;AROMASIN	4904650	JUL 07, 2006		ODE	OCT 21, 2006
			5246937	SEP 21, 2010	U-96		
	020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020363 003	FAMCICLOVIR;FAMVIR	5854267	DEC 29, 2015	U-267		
	020325 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
	020801 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
			5075114	DEC 24, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	020747 001	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 002	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 003	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 004	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 005	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 006	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5855912	FEB 28, 2015			
			5738872	FEB 28, 2015			
	020788 001	FINASTERIDE;PROPECIA	5571817	NOV 05, 2013	U-259		
			5886184	NOV 19, 2012			
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
			5886184	NOV 19, 2012			
			4377584	MAR 22, 2000	U-261		
			5942519	OCT 23, 2018	U-280		
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
	018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003	U-154		
			4626549	DEC 02, 2003	U-84		
	018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003	U-154		
			4626549	DEC 02, 2003	U-84		
	020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
					U-154		
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	019958 001	FLUTICASONE PROPIONATE;CUTIVATE				I-267	JUN 17, 2002
	020121 001	FLUTICASONE PROPIONATE;FLONASE				I-258	DEC 11, 2001
	020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5767251	JUN 16, 2015			
	020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5767251	JUN 16, 2015			
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
>ADD>	020937 001	GADOVERSETAMIDE;OPTIMARK				NCE	DEC 08, 2004
>ADD>	020975 001	GADOVERSETAMIDE;OPTIMARK				NCE	DEC 08, 2004
>ADD>	020976 001	GADOVERSETAMIDE;OPTIMARK				NCE	DEC 08, 2004
	021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
			5767082	JUN 16, 2015			
>ADD>	021061 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
>ADD>	021061 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
>ADD>	021062 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			4980470	DEC 25, 2007		NCE	DEC 17, 2004
>ADD>	021062 002	GATIFLOXACIN;TEQUIN	4808614	MAY 15, 2010			
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4379785	APR 06, 2005	U-118		
	020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 003	GLIMEPIRIDE;AMARYL				I-264	JUL 27, 2002
	020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL	5994348	JUN 07, 2015			
>ADD>	020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5994348	JUN 07, 2015			
>ADD>	020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5994348	JUN 07, 2015		NCE	SEP 30, 2002
>ADD>	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		D-50	MAY 13, 2002
	020491 001	IBUTILIDE FUMARATE;CORVERT	4689338	AUG 25, 2009	U-172		
	020723 001	IMIQUIMOD;ALDARA				NP	JUL 19, 2002
	021028 001	INSULIN HUMAN;VELOSULIN BR	4791111	DEC 23, 2005			
	020083 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020966 001	ITRACONAZOLE;SPORANOX	4267179	JUN 23, 2000			
	021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
	020564 001	LAMIVUDINE;EPIVIR	5905082	MAY 18, 2016			
	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
			5905082	MAY 18, 2016			
	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020406 001	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020406 002	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
			5422368	MAR 22, 2011	U-260		
			4599353	JUL 28, 2006	U-260		
			4652441	NOV 01, 2004			
	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4				NP	MAR 25, 2002
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	4584305	JUN 18, 2004	U-42		
	020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4943639	JUL 06, 2006		NCE	NOV 30, 2004
>ADD>	021035 001	LEVETIRACETAM;KEPPRA	4837223	JUN 06, 2006			
>ADD>			4943639	JUL 06, 2006		NCE	NOV 30, 2004
>ADD>	021035 002	LEVETIRACETAM;KEPPRA	4837223	JUN 06, 2006			
>ADD>			4943639	JUL 06, 2006		NCE	NOV 30, 2004
>ADD>	021035 003	LEVETIRACETAM;KEPPRA	4837223	JUN 06, 2006			
>ADD>			5708011	OCT 13, 2014	U-276		
	020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE				NP	JUL 28, 2002
	021045 001	LEVONORGESTREL;PLAN B				I-260	MAR 11, 2002
	019941 001	LIDOCAINE;EMLA					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020612 001	LIDOCAINE;LIDODERM					
	019777 006	LISINOPRIL;ZESTRIL				ODE	MAR 19, 2006
	019643 002	LOVASTATIN;MEVACOR	4374829	DEC 30, 2001			
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	021047 001	LUTEINIZING HORMONE;REPRONEX	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	021047 002	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
>ADD>	020922 001	MEQUINOL;SOLAGE				NP	AUG 27, 2002
>ADD>			5194247	MAR 16, 2010	U-294		
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	5470567	MAR 19, 2010	U-294		
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020969 001	METHOXSALEN;UVADEX				NCE	MAR 03, 2000
			4845075	APR 11, 2009		NP	FEB 25, 2002
	020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5036102	JUL 30, 2008	U-273		
	020682 001	MIGLITOL;GLYSET	4999375	MAR 12, 2008			
	020682 002	MIGLITOL;GLYSET	5514698	MAR 21, 2014		NP	JUN 30, 2002
	020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	019436 001	MILRINONE LACTATE;PRIMACOR	4639436	JAN 27, 2009	U-111		
	020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4639436	JAN 27, 2009	U-111		
	020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	020717 001	MODAFINIL;PROVIGIL	4313951	NOV 26, 2001			
			4313951	NOV 26, 2001			
			4177290	MAR 09, 1999			
	020717 002	MODAFINIL;PROVIGIL	5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
			4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
>ADD>	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				NCE	DEC 10, 2004
>ADD>	021009 001	NEDOCROMIL SODIUM;ABREVIA	4474787	OCT 02, 2006		NP	DEC 08, 2002
>ADD>			4760072	JUL 26, 2005			
	020933 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011			
	018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
	020714 001	NICOTINE;NICOTROL	5400808	JUN 08, 2010			
			4917120	APR 17, 2007			
			4800903	JAN 31, 2006			
			4793366	DEC 27, 2005			
			5167242	JUN 08, 2010			
			5501236	JUN 08, 2010			
			5186925	FEB 16, 2010			
	018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
	020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2004		NCE	APR 23, 2004
	021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
			5866601	FEB 02, 2016			
			5952375	FEB 02, 2016			
>ADD>	018841 004	OXAPROZIN;DAYPRO				PED	APR 29, 2000
>ADD>						NCE	OCT 29, 1999
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			5840754	MAY 22, 2015			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5840754	MAY 22, 2015			
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020262 001	PACLITAXEL;TAXOL				I-270	OCT 25, 2002
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
>ADD>	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
>ADD>	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
>ADD>	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
>ADD>	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
>ADD>	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-286		
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-286		
	021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
			5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
		4687777	JAN 17, 2006			
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
		4687777	JAN 17, 2006			
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
		4687777	JAN 17, 2006			
020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
020744 001	PORACTANT ALPHA;CUROSURF				NCE	NOV 18, 2004
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	MAR 25, 2011			
020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015			
		5714520*PED	SEP 22, 2015			
		5731355	MAR 22, 2015	U-217		
		5731355*PED	SEP 22, 2015	U-217		
		5731356	MAR 22, 2015	U-218		
		5731356*PED	SEP 22, 2015	U-218		
		5908869	MAR 22, 2015	U-270		
		5908869*PED	SEP 22, 2015	U-270		
075102 001	PROPOFOL;PROPOFOL				PC	OCT 17, 1999
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
020973 002	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5466810	JUN 10, 2014		I-271	SEP 30, 2002
		5514826	JUN 07, 2015			
		5569772	JUN 07, 2015			
		5629425	SEP 19, 2014			
		5659087	JUN 07, 2015			
		5710285	MAR 31, 2015			
		5731327	MAR 24, 2015			
		5731342	JAN 27, 2017			
		5747510	MAR 02, 2014			
		5808061	MAR 31, 2014			
		5811120	MAR 02, 2014			
		5843984	APR 14, 2017			
		5972383	MAR 02, 2014	U-287		
075094 001	RANITIDINE HYDROCHLORIDE;RANITIDINE HCL				PC	JAN 14, 2000
020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020903 001	RIBAVIRIN;REBETOL	5914128	DEC 22, 2017			
020272 007	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
		4804663	DEC 29, 2007	U-90		
020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	D-37	OCT 17, 2000
		5158952	OCT 27, 2009	U-90		
020680 001	RITONAVIR;NORVIR	5948436	SEP 13, 2013			
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
>ADD>	020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017			
>ADD>	019766 001	SIMVASTATIN;ZOCOR				I-277	NOV 22, 2002
>ADD>						I-278	NOV 22, 2002
>ADD>	019766 002	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
>ADD>						I-277	NOV 22, 2002
>ADD>	019766 003	SIMVASTATIN;ZOCOR				I-278	NOV 22, 2002
>ADD>						I-273	AUG 05, 2002
>ADD>	019766 004	SIMVASTATIN;ZOCOR				I-277	NOV 22, 2002
>ADD>						I-278	NOV 22, 2002
>ADD>	019766 005	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
>ADD>						I-277	NOV 22, 2002
>ADD>	021083 001	SIROLIMUS;RAPAMUNE				I-278	NOV 22, 2002
>ADD>						I-273	AUG 05, 2002
>ADD>			5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
>ADD>			5212155	MAY 18, 2010	U-291		
>ADD>			5308847	MAY 03, 2011	U-292		
>ADD>			5403833	APR 04, 2012	U-293		
			5536729	SEP 30, 2013			
	019640 005	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	019640 006	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	019640 007	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4703063	OCT 27, 2009			
	021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	074823 001	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 002	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 003	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 004	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-281		
	020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL				NCE	DEC 30, 1999
	020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73	NCE	DEC 30, 1999
			4755534	DEC 30, 2006	U-73		
	020846 001	TERBINAFINE;LAMISIL				NP	APR 29, 2001
						NCE	DEC 30, 1999
	019762 001	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	019762 002	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
			5354760	MAR 24, 2012			
	020707 001	TILUDRONATE DISODIUM;SKELID	4876248	JAN 30, 2010			
	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
			5965581	OCT 23, 2016			
			5972967	OCT 23, 2016			
	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
			5965581	OCT 23, 2016			
			5972967	OCT 23, 2016			
	020505 001	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 002	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 003	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 004	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020505 005	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020505 006	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN				I-256	NOV 30, 2001
>ADD>	020137 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
>ADD>	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5976573	JUL 03, 2016	U-295		
	020719 001	TROGLITAZONE;PRELAY				I-275	JUN 16, 2002
	020719 002	TROGLITAZONE;PRELAY				I-275	JUN 16, 2002
	020719 003	TROGLITAZONE;PRELAY				I-275	JUN 16, 2002
	020720 001	TROGLITAZONE;REZULIN				I-276	JUN 16, 2002
	020720 002	TROGLITAZONE;REZULIN				I-276	JUN 16, 2002
	020720 003	TROGLITAZONE;REZULIN				I-276	JUN 16, 2002
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020900 001	UREA, C-13;PYLORI-CHEK BREATH TEST				NCE	SEP 17, 2001
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
	020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
>ADD>	020547 001	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		I-268	SEP 17, 2002
	020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		NCE	JUL 26, 2004
			4778054	OCT 18, 2005			
			4811731	JUL 29, 2006			
			5035237	JUL 30, 2008			
			5360817	NOV 01, 2011			
			5648379	JUL 15, 2014	U-274		
			4627432	DEC 09, 2003			

New 20th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8312

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $90.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/98)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence